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Abstract 
In the absence of a successful vaccine against HIV-1, alternative means to cope 
with the HIV pandemic have been explored. Antiretroviral (ARV) treatment 
is commonly prescribed to HIV-infected individuals in an attempt to control 
the infection. However, ARV treatment is very rigorous and generally com-
prises a highly toxic and costly multi-drug regimen designed for strict, life-long 
adherence. ARV treatment interruption is an alternative treatment strategy 
designed to maximize clinical benefits and alleviate some of the complications 
associated with continuous treatment. It is theorized that treatment interrup-
tion can reset the virological setpoint by inducing controlled resurgences of 
virus to boost HIV -specific ens+ T cell activity to control viral replication. 
Dynamical systems analysis is a mathematical tool used to describe the be-
havior of complex systems. This allows an unobtrusive, safe way to test treat-
ment interruption regimens. I have developed a novel mathematical model 
that describes the dynamical interactions between HIV-specific T cell and virus 
populations for two clinically-defined subgroups of HIV-1-infected individuals 
called fast and slow progressors. The model is based on antiviral activity 
imposed by HIV-specific ens+ T cells that specifically target the virus by 
removing virally-infected cells and the model accurately mimics clinical dis-
11 
ease progression patterns in these subgroups. Model results accurately predict 
that treatment interruption induces resurgence of virus to boost HIV-specific 
ens+ T cell activity in both subgroups, but does not reset the virological 
setpoint in either. These results are experimentally corroborated through an 
assessment of quantitative and qualitative changes in HIV -specific ens+ T 
cell activities when virus loads are high (off-treatment) and low/ undetectable 
(on-treatment). 
In this thesis, I provide an introduction to HIV and dynamical systems, a 
complete analysis of the model derived to describe HIV immunopathogenesis, 
a report on clinical and experimental observation of a small cohort of HIV -1-
infected individuals and a description of the integration of the mathematical, 
clinical and experimental results. 
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Chapter 1 
Introduction 
Human immunodeficiency virus type 1 (HIV-1), the causative agent of ac-
quired immune deficiency syndrome (AIDS), was isolated and identified in 1983 
[Gallo et al., 1984]. HIV is a retrovirus: it stores its genetic information as 
single-stranded ribonucleic acid (RNA) molecules instead of double-stranded 
deoxyribonucleic acid (DNA) and reverses the normal genetic writing process 
by converting viral RNA to viral DNA as part of its life cycle. HIV is a mem-
ber of a subgroup of the retrovirus family known as the lentiviruses because it 
causes disease slowly. In the absence of treatment, infection generally spans a 
period of approximately 10 years. HIV and AIDS remain at pandemic levels 
with an estimated 40 million people living with HIV infection and 5 million 
newly infected individuals in 2005. More than 25 million people have died of 
AIDS since 1981 and there is no known cure [UNAIDS/WHO 2005 report]. 
1 
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1.1 Host Infection 
HIV is transmitted via blood or other body fluids, and infection with HIV 
always results in chronic infection. Following infection with HIV, the amount 
of virus detectable in the blood of the host, called the virus load, rises dramat-
ically. This increase in virus load is associated with flu-like symptoms, tending 
to last for a few weeks to months, which disappear as the virus load recedes 
to a lower stable level called the virological setpoint. The infected individ-
ual generally remains asymptomatic for years until eventually succumbing to 
AIDS. 
The definition of AIDS is ambiguous. In the United States, an HIV-infected 
individual is said to have AIDS if their helper T cell count falls below 200 per 
microlitre (ul) of peripheral blood [Centers for Disease Control, 2005]. In 
Canada, an individual is considered to have AIDS if they develop an AIDS-
defining illness. There are cases of HIV-infected individuals who develop AIDS, 
but following salvage or late treatment treatment regimens1 , no longer have 
AIDS according to these definitions. 
1.2 HIV Immunopathogenesis 
HIV immunopathogenesis is characterized by three phases: the acute phase, 
the chronic phase and AIDS. Figure 1.1 is a schematic graph showing how T 
cell and virus populations change throughout pathogenesis. 
1 Salvage Treatment: A drug combination that is used after other combinations have 
failed. Often, salvage treatment is used to refer to regimens designed to combat highly 
resistant HIV. Also called rescue therapy. 
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Figure 1.1: HIV immunopathogenesis - Adapted from Microbiology and Im-
munology online- University of South Carolina- School of Medicine 
In the early phase of acute HIV infection, the virus load increases reaching 
concentrations of up to 100 million copies HIV RNA per millilitre of plasma 
[Piatak et al., 1993; Mellors et al., 1995]. The presence of the virus at high 
levels in the host induces potent cellular immune responses throughout the 
following weeks. These immune responses act to lower the viral load by ef-
ficiently removing infected cells from the system until the imposed pressure 
from the cellular immune response induces a state where the T cell and virus 
populations are roughly in equilibrium. This equilibrium or balance implies 
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that each population is in a stable state whereby they stay at relatively con-
stant levels. The virus load at the equilibrium state (the virological or viral 
setpoint) is a strong predictor of the rate of disease progression [Altfeld et 
al., 2005; Mellors et al., 1995; Notermans et al., 1998]. Establishment of a 
virological setpoint generally marks the resolution of the acute phase and the 
beginning of the chronic phase of infection. During the chronic phase, the 
virus persists at setpoint levels and continuously stimulates the host immune 
system via ongoing replication. It is during the chronic phase of infection that 
the helper T cell (CD4+ T cell) population is slowly and steadily depleted. 
This is the hallmark of HIV infection. The exact reason for this apparent slow 
steady depletion of these cells remains elusive. 
1.3 Cellular Infection 
HIV preferentially infects helper T cells; the cells that coordinate cellular im-
mune reponses [Dalgleish et al., 1984; Klatzmann et al., 1984; McCune, 2001]. 
This leads to their eventual depletion and results in the collapse of the im-
mune system. The virus attaches to helper T cells via a high affinity interaction 
between the cell-surface molecule CD4 (T4 antigen) and the external gp120 
portion of the viral envelope protein complex. This binding is associated with 
coreceptor binding to cellular chemokine receptors CCR5 or CXCR4 on the 
CD4 + cell. Whether the virus binds co receptor CCR5 or CXCR4 determines 
the tropism of the virus. Individuals who lack a CCR5 coreceptor on their T 
cells are virtually 100% resistant to HIV infection indicating the necessity of 
this co-receptor for cell infection to occur. The union of gp120 and CD4 causes 
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a conformational change to occur in the gp120 glycoprotein which allows an-
other part of gp120 to bind either CCR5 or CXCR4. After this secondary 
interaction, the transmembrane portion of the envelope protein gp41 under-
goes a conformational change and embeds a fusogenic part of itself into the 
host cell membrane [Levy; 1996]. The host cell and the viral envelope fuse and 
the viral contents are released into the cytoplasm of the host cell. The viral 
capsid is lost and viral RNA begins to be transcribed via reverse transcriptase 
into viral double-stranded DNA (dsDNA) called the provirus. This dsDNA 
gets integrated into the host cell DNA via another viral constituent enzyme 
called integrase, rendering the cell infected for life. The integrated DNA is 
called the integrated provirus. The integrated provirus serves as a template 
for the synthesis of viral RNA. Cellular activation is necessary for integration 
of the proviral HIV DNA into the host cell genome after transportation of the 
pre-integration complex into the nucleus. When the infected cell is activated, 
viral RNA is synthesized and moves into the cytoplasm. Viral messenger RNA 
(mRNA) is subsequently translated into structural proteins and enzymes nec-
essary for synthesis of viral proteins and assembly of new virions. The mRNA 
carries information that codes for viral proteins and enzymes necessary for 
synthesis of viral proteins and assembly of new virions. Viral RNA and as-
sociated proteins are packaged into new virus particles that mature into new 
infectious virions. This assembly begins at the cell membrane where the virion 
forms and buds from the cell surface membrane. These new virions undergo 
further maturation whereby the structural components undergo further pro-
cessing following budding. 
Viral DNA integration into the host-cell genome is irreversible. Some cells 
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become virus producers. Other cells remain latently infected. Latent infection 
means that the cell is infected; the provirus is present, but the cell has not 
yet become activated to begin the viral replication cycle. Some cells may 
never become activated, or they may become activated at a later time point 
in disease progression. Even if the virus is cleared from the bloodstream, it 
can lie dormant in latently infected cells, later activated to produce teams of 
new viral progeny. 
All CD4+ T cells are all susceptible to infection by HIV [Janeway et al., 
2001; Douek et al., 2003; Ribeiro et al., 2002]. However, studies show that 
HIV preferentially infects HIV-specific CD4+ T cells [Douek et al., 2002]. The 
preferential infection of HIV -specific CD4 + T cells means that these cells are 
preferentially depleted as well. More on this follows in Chapter 2. 
1.4 Immune Response 
The immune response to HIV is very much the same as the immune response 
to any viral infection. This response includes the activation of both cellular 
and humoral immunity. Once the virus breaches the mucosal barriers, resident 
phagocytic cells such as macrophages and dendritic cells (DC), "take-up" viral 
antigens and home to the local draining lymph node. En route to the lymph 
node, these cells change functionally and phenotypically to become extremely 
proficient antigen-presenting cells (APC). DC are the most potent inducers 
of specific immune responses and are considered essential for the initiation 
of primary antigen-specific immune responses. Antibodies are produced as 
part of these primary antigen-specific responses to clear the virus from the 
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body. These antibodies can be detected in the blood during infection and are 
used to diagnose infection. When antibodies are detectable in the plasma or 
blood, an individual is said to have seroconverted and is deemed HIV positive. 
This usually occurs within six months of exposure to HIV and is the clearest 
evidence of an adaptive immune response to infection with HIV. 
A vital part of the adaptive immune reponse is the cellular or cell-mediated 
response. It involves coordinated interactions between activated antigen-specific 
eD4+ and ens+ T cells that leads to the destruction of virally-infected cells 
by antigen-specific ens+ T cells. This creates a paradoxical situation. The 
fact that the HIV -specific eD4 + T cells, which are necessary for an efficient 
immune response against the virus, become targets for HIV -specific ens+ T 
cells causes further decay in the eD4 + T cell population. The HIV -specific 
eD4+ T cell population, on average, comprises approximately 1/100 total 
eD4+ cells in the chronic phase of infection [Douek et al., 2002]. 
HIV viral peptides can only be recognized via HIV -specific T cell receptor 
(TeR) major histocompatability complex (MHe) interactions. When an HIV 
peptide is presented via a TeR:MHe II interaction by an APe to an HIV-
specific eD4 + T cell, the cell becomes activated. The activation of the cell 
causes it to proliferate and differentiate into an effector cell. As effector cells, 
HIV-specific eD4+ T cells act to coordinate other cells of the immune system 
to try to eradicate the virus from the host. During acute infection in vivo, 
rapidly proliferating HIV-specific eD4+ T cells, in transition from naive to 
full effector phenotype, are highly susceptible to HIV infection [Douek et al., 
2002; Mehandru et al., 2004; Qingsheng et al., 2005]. 
HIV-specific eD4+ T cells help other cells, such as HIV-specific ens+ T 
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cells, proliferate and differentiate into effector cells by secreting cytokines such 
as interleukin-2 (IL-2). IL-2 is aT cell growth factor and is essential for the 
maintenance of an effective cellular immune response. ens+ T cells produce 
a cytokine called interferon-gamma (IFN-"'(), that has antiviral properties. 
HIV-specific ens+ T cells recognize HIV antigens in the context of an 
MHe class !-peptide complex on an APe and acquire a range of antiviral ac-
tivities including the ability to kill virally-infected cells. ens+ T cells that kill 
infected cells are called cytotoxic T lymphocytes ( eTL). eTL can kill virally-
infected cells using a perforin-granzyme-based pathway. Perforin functions to 
"perforate" the membranes of virally-infected cells to allow entry of the enzyme 
granzyme, to trigger apoptosis of the infected target cell. eTL can kill their 
targets rapidly because they store these preformed cytotoxic proteins in inac-
tive forms in a lytic granule and can kill many targets in succession [Janeway et 
al., 2001; Isaaz et al., 1995]. In vitro and in vivo studies have shown that eTL 
aptly kill virally-infected cells [Macatonia et al., 1991; Musey et al., 1997]. The 
best evidence for the clinical importance of the control of HIV-infected cells 
by HIV-specific eTL comes from studies relating the numbers and activity 
of ens+ T cells to viral load. The number of HIV-specific ens+ T cells is 
inversely correlated to plasma RNA viral load: when HIV-specific ens+ T cell 
numbers are high, the virus load is low. Similarly, patients with high levels of 
HIV-specific ens+ T cells show slower progression of disease than those with 
low levels [Landay et al., 1993; Borrow et al., 1994; Betts et al., 2005; Hess 
et al., 2004]. HIV-specific ens+ T cells can also carry out effector functions 
as non-cytolytic ens+ T cells by producing antiviral cytokines such as IFN-"Y 
and tumor necrosis factors (TNF)-a and (3. IFN-"'( directly inhibits viral repli-
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cation, and also induces the increased expression of MHC class I and other 
molecules involved in peptide loading of the newly synthesized MHC class I 
peptides in infected cells. This increases the chance that infected cells will be 
recognized as target cells for cytotoxic attack [Janeway et al., 2001; McMichael 
& Rowland-Jones, 2001]. TNF-a and f3 can act synergistically with IFN-1 to 
enhance the antiviral attack. Ultimately, the immune response against HIV 
controls but does not eradicate HIV from the host. 
As part of the cellular immune response against HIV, some HIV-specific 
T cells become long-lived memory cells. These memory cells, upon secondary, 
tertiary, etc. encounters with HIV, are primed to impose subsequent immune 
responses when re-challenged by the virus. The development of immunologi-
cal memory is the hallmark of the adaptive immune response and is why we 
can become immune to some viruses, such as Varicella-Zoster Virus (VZV): 
the virus that causes chicken pox and shingles [Janeway et al., 2001]. Sec-
ondary immune responses are typically fast and efficient: the host does not 
know that the immune system has been re-challenged. Once the infectious 
agent has been cleared from the body, the immune response effectively ends. 
However, because HIV is a chronic infection, the processes of T cell activation, 
proliferation and differentiation are ongoing. In some HIV-infected individu-
als, the continued presence of HIV can somehow impair these processes. For 
example, many studies have shown that HIV can eventually prevent the ter-
minal differentiation of effector memory T cells into fully-functional mature 
effector cells (CD45RA+ CCR7-) [Champagne et al., 2001; Van Baade, 2002; 
Shankar et al., 2000; Hess et al., 2004; Yue et al., 2004]. Cytokines necessary 
for maintenance of effective proliferative responses and proper maturation are 
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also reduced in some HIV-infected individuals [McNeil et al., 2001; Kawamura 
et al., 2003]. Naturally, impairment of any stage of the immune response 
provides the virus an advantage. 
As previously indicated, several factors contribute to the slow steady de-
pletion of CD4+ T cells. One of these is the direct cytopathocity of HIV. 
Each infected cell that becomes activated as part of an immune response, not 
necessarily against HIV, becomes a virus factory. Eventually, these cells may 
succumb to death by continuous viral budding or via apoptotic mechanisms 
mediated by CTL. 
1.5 Treatment 
In the absence of a successful vaccine, alternative means are needed to cope 
with HIV. Presently, the only somewhat practical solution to the problem is 
antiretroviral drug treatment. Antiretroviral treatment effectively reduces the 
virus load in most HIV-1-infected individuals. There are currently four ma-
jor classes of antiretroviral drugs: nucleoside analogue reverse transcriptase 
inhibitors (NRTis), nonnucleoside reverse transcriptase inhibitors (NNRTis), 
protease inhibitors (Pis) and fusion inhibitors (Fis). These drugs act at dif-
ferent points during the infection/replication process but all suppress viral 
replication. Fis prevent the host cell from becoming infected. NRTis and 
NNRTis prevent the provirus from being produced. Pis on the other hand act 
subsequent to infection of the host cell to prevent the formation of new virions. 
Ultimately, these drugs should be taken in combination to reap the full bene-
fits of combination therapy. Highly active antiretroviral treatment (HAART) 
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generally comprises a combination of three NRTis, NNRTis and Pis and has 
proven quite effective in suppressing viral replication and reducing virus loads 
to undetectable levels, thereby prolonging the lives of HIV-infected individuals. 
However, due to toxicity of the drugs to the individual, adherence problems are 
prevalent among HAART users [Office of AIDS Research Advisory Council, 
2004]. 
The toxicity of HAART can lead to secondary health problems and the 
necessity for additional prescription drugs to control clinical complications. In 
addition, antiretroviral drugs are quite costly to manufacture and distribute. 
Strict adherence is important in the context of HAART since the virus repli-
cates very quickly. Non-adherence is associated with viral rebound and can 
induce the emergence of drug resistant virus that repopulates the host. In 
short, it is potentially dangerous to randomly interrupt drug treatment once 
it has been initiated because it is not known what the short-term or long-term 
effects will be. 
Antiretroviral treatment has also been associated with changes in HIV-
specific CDS+ T cell activity while suppressing viral replication and thus re-
ducing antigenic stimulation [Casazza et al., 2005; Lacabaratz-Porret et al., 
2003; Appay et al., 2002]. Without treatment, a high number of HIV-specific 
CDS+ T cells often persists into late infection and can still be detectable when 
AIDS develops in some HIV-1-infected individuals [Appay et al., 2002]. How-
ever, it is the quality, not just the quantity of these cells that is important 
in determining how an individual progresses through disease. This will be 
discussed further in Chapter 6. Since treatment can be initiated at any point 
during infection, it is important to investigate the clinical and immunological 
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effects of introducing and withdrawing treatment, such as changes in HIV-
specific CDS+ T cell activity, during the acute and chronic phases of infection 
to maximize potential benefits of treatment regimens during these phases. For 
example, studies show that initiation of antiretroviral treatment during the 
acute phase of infection preserves HIV-specific T cell populations to promote 
better prognoses and to reduce virological setpoints [Borrow et al., 1994; Alt-
feld et al., 2001; Rosenberg et al., 2000; Oxenius et al., 2000]. 
The chronic phase of infection is associated with an equilibrium state of 
the host. Antiretroviral treatment perturbs this equilibrium state by reducing 
the virus load dramatically. Therefore, it is vital to understand how the im-
mune system players, such as the HIV -specific T cell populations, respond to 
this perturbation before attempting to assign treatment interruption regimens 
[Nikolova et al., 2005; Benito et al., 2003]. 
1.5.1 Treatment interruption 
The goal of any interruption scheme is to maintain clinical benefits of treat-
ment, such as low or undetectable virus load, while concurrently reducing 
drug toxicity to the individual. Monitored or structured treatment interrup-
tion studies allow an investigation into the clinical and immunological effects 
of missing or interrupting treatment. Studies show that HIV-specific immune 
responses can increase during a treatment interruption [Garcia et al., 2000; 
Montaner, 2001]. This "boost" in the HIV-specific immune response (due 
to an increase in virus antigen load) does not necessarily represent construc-
tive immune enhancement [Ortiz et al., 2002]. There is variability in results 
from clinical trials. Some provide evidence to support constructive immune 
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enhancement and others provide evidence to refute this. 
One of the reasons for variablity in experimental and clinical studies is the 
variability in test subjects. No two HIV-infected individuals progress through 
disease in exactly the same manner. Therefore, unless we know ahead of time 
how an individual is progessing through disease, only generalizations can be 
made as to how antiretroviral treatment will affect them, both clinically and 
immunologically, or when it is advisable to interrupt treatment. If we can 
pre-classify HIV-infected individuals in terms of disease progression, we may 
more confidently determine whether or not they will benefit from treatment 
interruption. 
1. 6 Fast and slow progressors 
Studies have shown that HIV-infected individuals can be subgrouped with re-
spect to disease progression rates [Jansen et al., 2004]. Each HIV-infected 
individual in this study fits into one of two categories; those who reasonably 
control viral replication in the absence of treatment and those who do not. 
Reasonable control implies a balance between the HIV -specific CDS+ T cells 
and the virus whereby the virus load is maintained at levels associated with 
slow or inapparent disease progression (low virological set point). More specifi-
cally, if an HIV-infected individual experiences rapidly falling CD4 counts and 
rapid viral rebound following treatment interruption, they are classified as a 
fast progressor. If an HIV-infected individual maintains a stable CD4 count 
and a virus load at a low level following treatment interruption, they are clas-
sified as a slow progressor. For the purposes of this thesis, a controllable or 
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low level comprises an average off-treatment virus load less than or equal to 
4.5 (logarithmic scale) RNA copies per millilitre (ml) of blood. Conversely, 
an uncontrollable level comprises an average off-treatment virus load greater 
than 4.5 RNA copies per ml of blood. 
The balance between the HIV-specific ens+ T cells and the virus in the 
HIV-infected study subjects can be examined by measuring the HIV-specific 
ens+ T cell activity on and off-treatment when the virus load is both low 
(undetectable) and high, respectively. The study participants in the cohort 
were not engaged in a structured treatment interruption trial, but periodically 
interrupted treatment either of their own volition, or under the advice of their 
clinician. 
1. 7 Why use modeling? 
Since the outcome of a clinical trial may not be desirable and the immunolog-
ical effects of interrupting treatment are not yet clearly defined, it is prudent 
to explore alternative means to investigate the effects of interrupting treat-
ment. Mathematical modeling allows for an unobtrusive, safe means by which 
to test various treatment interruption strategies. Mathematical models are 
the tools we use to gain theoretical access to the real world. I have developed 
a novel mathematical model to examine the effects of treatment interruption 
and to investigate whether or not treatment interruption can be used to boost 
immune HIV-specific ens+ T cell responses to lower the virological setpoint. 
In the following chapter, I provide an introduction to mathematical mod-
eling of dynamical systems and describe how the model will be analysed and 
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how this analysis will be used to answer some of the questions raised here. 
Chapter 2 
Modeling of dynamical systems 
No human investigation can be called real science if it cannot be 
demonstrated mathematically. - Leonardo da Vinci (1452-1519) 
This chapter is devoted to defining mathematical concepts using theorems 
and mathematical definitions. See introductory differential equations texts, 
such as Boyce and DiPrima [2004] for details. 
2.1 Mathematical Models 
Mathematical modeling of dynamical systems is a very useful tool for analyzing 
how a system evolves in time and how it reacts to perturbations. Mathemat-
ical models, in general, are sets of equations that describe the behaviour of a 
system via dependent and independent variables. The HIV-infected immune 
system can be modeled as a dynamical system of many variables including im-
mune cell and virus populations. HIV pathogenesis is associated with changes 
in the size of each variable population as the immune system attempts to elim-
16 
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inate the virus from the host. The state of the HIV-infected immune system 
at any time t is specified by the values of the variables at t. Mathematical 
models that describe this system involve nonlinear differential equations be-
cause the variables in the model usually do not change in direct proportion 
to other variables. In general, exact solutions cannot be found for nonlinear 
systems. Therefore, analysis of such nonlinear dynamical systems is commonly 
approached in a qualitative manner, especially when the system involves many 
variables. This is because the components of the equations that make up the 
system are not known precisely. Dynamical systems analysis allows us to find 
the eventual behaviour of a system without having to know parameter values 
accurately or even having to know the terms of the system precisely. By ana-
lyzing the system in a qualitative manner, we do not have to rely on numerical 
techniques which, in turn, rely on the validity or precision of the equations 
from which they originate. 
In this study, I analyze the system by determining the stability of the 
system in the neighborhood of equilibrium points, or fixed points, according 
to the following protocol: 
• finding the fixed points of the system of equations 
• linearizing the system in the neighborhoods of the fixed points 
• determining the eigenvalues of the resulting linearized equations to assess 
stabilities of fixed points 
This protocol allows the determination of the stability properties of any 
fixed points that may exist. Maple software was used to determine all fixed 
points and eigenvalues. 
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2. 2 Finding the Fixed Points 
Fixed points are locations in phase space. Phase space is the set of all possible 
states of a dynamical system. The dimension of the phase space is the number 
of variables in the system. The path in phase space traced out by a solution of 
a dynamical system is called an orbit. A fixed point is a special type of orbit 
that is just a single point in phase space as the system changes with time. 
Phase plane analysis is a way to determine the locations and stabilites of 
fixed points in phase space. It characterizes a system and its solutions in a 
single picture called a phase portrait or a phase diagram. Figure 2.1 is a phase 
diagram illustrating the location of a single fixed point in three-dimensional 
phase space. This particular fixed point is an asymptotically stable spiral node 
and is located at the point (x, y, z) = (2, 2, 4). All orbits in (x- y- z)-phase 
space spiral inward to this stable fixed point. Directional arrows are not shown 
in the diagram. 
A fixed point, also known as an equilibrium or steady state, corresponds 
to a motionless state of a system. The fixed point can be stable or unstable, 
depending on nature of the eigenvalues of the fixed point. The fixed point in 
Figure 2.1 is (asymptotically) stable in that it attracts nearby orbits in phase 
space. A fixed point that is unstable repels nearby orbits in phase space. 
Theorem 2.2.1. Consider the nonlinear system of ordinary differential equa-
tions 
dxi dt = fi(x), for i = 1, ... , n (2.2.1) 
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solution of the equation: x(t) =X: that satisfies the system of equations for all 
time. 
Every fixed point inherently has a stability property. To determine the 
stability property of a fixed point, we must solve the eigenvalue problem. To 
do this, we must first understand ideas and techniques of linear algebra. 
2.3 Solution of a system of linear ODEs 
Solving a system of linear (or nonlinear) differential equations can be facilitated 
using linear algebra. Linear algebra is the part of algebra that deals with the 
theory of linear equations and linear transformation. We use these theories to 
solve the eigenvalue problem. 
A set of n simultaneous linear algebraic equations in n variables, 
an1X1 + an2Xn+ · · · + annXn = bn 
can be written as 
Ax=b, 
where then x n matrix A and the vector bare given and the components of 
x are to be determined. 
The equation 
Ax=b 
can be viewed as a linear transformation that transforms a given vector x into 
CHAPTER 2. MODELING OF DYNAMICAL SYSTEMS 21 
a new vector b. To find such vectors, we set 
h= AX 
where A is a scalar proportionality factor, and seek solutions of the equations 
Ax=.Xx 
or 
(A- .XI)x = 0, 
where I is the identity matrix. The latter equation has nonzero solutions if 
and only if .X is chosen so that 
det(A- .XI)= 0. 
This equation is called the characteristic equation. Values of A that satisfy 
the characteristic equation are called eigenvalues of the matrix A. Thus, the 
eigenvalues of A are the roots or solutions of the characteristic equation. 
It turns out that the eigenvalue problem for systems of linear algebraic 
equations is connected to the solution of systems of linear differential equa-
tions. The solution of a system of linear differential equations reduces to the 
eigenvalue problem for algebraic equations in the following way. 
An non-autonomous system of n linear differential equations 
Xn = an1(t)x1+ an2(t)x2+ · · · + ann(t)xn 
can be written as 
X.= A(t)x, 
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where x1 , x2 , ... , Xn are the components of a vector x, and a11 (t), ... , ann(t) 
are the elements of ann x n matrix A(t). 
The eigenvalues of a matrix A can be used to find solutions for differential 
equations in the following way: 
Theorem 2.3.1. The system of differential equations x = Ax has solution 
x(t) = cve>-t if and only if for the matrix A, .A is an eigenvalue and v its 
corresponding eigenvector. 
2.4 Nonlinear systems of ODEs 
To linearize a nonlinear system of differential equations x = f(x) near any 
point x, we calculate and solve the Jacobian matrix of the system. 
Definition 2.4.1. The Jacobian matrix is the matrix of all first-order partial 
derivatives of a vector-valued function. It represents the best linear approxi-
mation to a differentiable function near a given point. 
Given the system x = f(x), we linearize around a fixed point using the 
Jacobian to obtain x = Jx, where J is evaluated at the fixed point. 
Consider the vector-valued function that contains the real-valued compo-
nent functions f 1 (x1 , x2) and f2(x 1 , x2). The partial derivatives of these func-
tions can be organized in a 2 x 2 matrix as follows: 
(2.4.1) 
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The characteristic equation and eigenvalues are found by applying the rules 
described for linear systems. However, instead of solving the eigenvalue prob-
lem using the matrix A (see section 2.3), we solve 
Jx= .Ax 
or 
(J- .AI)x = 0, 
where the Jacobian matrix J takes the place of the matrix A. Thus the 
eigenvalues can be found by solving the characteristic equation 
det(J- .AI) = 0. 
The solutions of the characteristic equation are precisely the eigenvalues of the 
matrix J. 
2.5 Stability of a fixed point 
The stability properties of fixed points for nonlinear systems are generally 
the same as for linear systems in the neighborhood of the fixed point. From 
the solutions of linear systems we gain information about the stabilites of fixed 
points from direct inspection of the eigenvalues. Eigenvalues can be real-valued 
or complex. Complex eigenvalues always exist in pairs and cause oscillatory 
effects in system solutions. If the real parts of all eigenvalues are negative, 
then the fixed point is stable. 
For stable fixed points, all solutions with initial conditions in the neighbor-
hood of the fixed point will approach it as t --+ oo. If one or more eigenvalues 
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of a fixed point have positive real parts, the fixed point is unstable. Some 
or all of the solutions with initial conditions starting in the neighborhood of 
the fixed point will diverge from it as t ---+ oo. Thus, upon inspection of the 
real parts of the eigenvalues for a given nth_order nonlinear system of ordinary 
differential equations, the stability of the given fixed point can be determined. 
Fixed points can be locally or globally stable. A fixed point is locally stable 
with orbits from nearby initial conditions tending to the stable fixed point if 
the eigenvalues of a linearized system have negative real parts. A fixed point 
is globally stable if all initial conditions have orbits tending to the stable fixed 
point. 
So far, I have described how to obtain qualitative information about non-
linear systems of equations without having to solve them. The determination 
of fixed points and their stabilities based on the nature of the eigenvalues pro-
vides a geometric picture of the system solutions. In order to further assess the 
qualitative nature of a dynamical system, bifurcation theory can be employed. 
2.6 Bifurcation Analysis 
Bifurcation analysis is a powerful tool in dynamical systems. It allows a vi-
sualization of qualitative changes that may occur in a dynamical system as a 
single parameter is varied, and tells us about the sensitivity of the system to 
parameter changes. Its power lies in the fact that the system behaviour and 
how it reacts to perturbations (changes in parameter values) can be known, 
without having to know exact parameter values. Approximations or estimates 
of parameter values provide a starting point from which these behaviours can 
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be examined, and are usually obtained experimentally. 
Qualitative changes in a system can be visualized by generating bifurcation 
diagrams. A bifurcation diagram is a plot which gives fixed point solutions as 
a function of a (control) parameter. This plot represents all possible long-term 
behaviours of the system as the parameter is varied. The diagram is made up 
of branches that are either solid or dotted lines representing the locations of 
stable or unstable fixed points of the system, respectively. 
Treatment is represented by a parameter in the model developed for this 
thesis. Since this parameter represents an external stimulus on the system (the 
system functions normally in the absence of this stimulus), its value can be 
varied in a controlled way to see how the system reacts according to changes 
in fixed points and their stabilites. Therefore, bifurcation analysis will allow 
a visualization of the effects of treatment on the system. 
A bifurcation in mathematics involves the divergence of the eventual state 
of a dynamical system. At a bifurcation value of a parameter, the qualitative 
nature of the solution of the system changes in that the number of fixed points 
and/ or the stability of fixed points changes. 
Solutions are different on either side of a bifurcation point. For example, if 
a critical parameter changes, a fixed point that once was stable, may become 
unstable, as is the case in a transcritical bifurcation. A solution that may 
represent a undesirable state for an HIV-infected individual may involve stable 
low levels of T cells and detectable virus load in the absence of treatment. A 
more favorable state may be induced using treatment. Treatment lowers the 
virus load to undetectable levels and generally raises T cell counts. Since 
some system behaviours may be harder to change than others that may be 
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highly sensitive to small pertubation or change, it is necessary to study the 
mechanisms by which various system behaviours arise before attempting to 
manipulate the system. 
Bifurcation analysis is also useful when examining potential qualitative 
changes that may occur when other parameters in the system are varied. In 
this study, bifurcation theory will be used to test the effects of modulating 
treatment efficacy on the system and to examine the effects of varying a pa-
rameter that represents the removal rate of infected cells from the system. 
(Refer to Chapter 4.) 
2.6.1 Types of bifurcations 
There are several common types of bifurcations. A saddle-node bifurcation is a 
local bifurcation in which two fixed points of a dynamical system annihilate one 
another. Figure 2.2 is a bifurcation diagram showing a saddle-node bifurcation. 
The phase space variable is x and the control parameter is c. The bifurcation 
point is at c=O and x = 0 ((c, x) = (0, 0)). Stable and unstable fixed points are 
drawn as solid and dotted lines, respectively. The diagram shows all possible 
long-term behaviours of x for a range of values for c. For example, when c=l, 
there are two fixed points: one is stable (solid branch) and one is unstable 
(dotted branch). 
A saddle-node bifurcation is the most common (generic) type of bifurcation 
in biological systems. However, saddle-node bifurcations do not arise for the 
model developed for this thesis. Rather, transcritical bifurcations are seen. 
Transcritical bifurcations are saddle-node bifurcations but with a special kind 
of symmetry in the equations, albeit not obvious. The equations in the model 
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Plotting the numerical solutions of a system gives us trajectories or time 
series of each variable in the system. This is a another graphical method that 
allows us to obtain information about a system and its solutions. Bifurcation 
diagrams give us a much broader view of the system behaviour because we can 
visualize many trajectories at one time. 
2.7 The Basic Model- A Dynamical System 
Perhaps the most well known dynamical system describing HIV pathogenesis 
is that of Perelson et al. [1995]. This basic model describes the rate of change 
of three variables: uninfected target cells, T, infected target cells, T*, and 
virus particles, V, at any time t. The equations for this basic model are as 
follows: 
dT 
s + pT ( 1-~) - drT- kVT (2.7.1a) dt Tmax 
dT* kVT- 8T* (2.7.1b) -
dt 
dV N8T*- cV (2.7.1c) -
dt 
The parameters are s, p, Tmax' dr, k, 8, N and c and represent rate con-
stants. Uninfected target cells enter the system from the thymus at a constant 
rate s. The growth of this population is assumed to be logistic in that it can 
only grow until it reaches a carrying capacity T max. This carrying capacity 
is regulated by homeostatic mechanisms that regulate overall T cell numbers: 
there is a finite number of cells that can occupy the body at any given time. 
p is the intrinsic growth rate. T cells will ultimately die at some constant rate 
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dr, also as part of normal homeostatic mechanisms. 
When the virus enters the system, the susceptible uninfected target cell 
population becomes infected at rate k (proportional to T and V). This creates 
the population of infected target cells, T*, whose members die at a constant 
rate 6. As each infected cell dies a certain number of virions ( N) are released 
into the body. The virus also dies by natural processes at a constant rate c. 
The model predicts a single stable fixed point (T, r*, V) with positive fixed 
point coordinates. These coordinates vary according to the parameter values 
selected. 
This basic model has allowed crucial insights into the 'fast' dynamics of the 
virus and how it reacts to antiretroviral treatment. Antiretroviral treatment is 
introduced to the equations as a parameter that modifies the infection rate k 
or the production rate of virus N 6. The viral turnover rate is extremely high; 
higher than previously estimated or assumed [Perelson et al., 1995; Ho et al., 
1995]. Numerous other models utilize the fundamental concepts of this basic 
model as it quite elegantly and simplistically describes the general behaviours 
of the variables T, T* and V and how they change together in time both in 
the presence and absence of treatment. 
Perelson has had many collaborations to develop an array of mathematical 
models that describe various aspects of HIV infection. Essunger and Perelson 
[1994] analyze models that describe the interactions between virgin, activated 
and memory CD4+ T cells and HIV. These models use a previously developed 
model as a template [McClean & Nowak, 1992] but are novel in their explicit 
treatment of a latent stage in HIV infection. All terms in the models are 
expressed in predator-prey, logistic or density dependent forms. 
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Callaway and Perelson [2002] describe a set of models that are derived from 
the standard model to explain sustained low on-treatment viral loads. These 
models include quiescent, chronically-infected and latently-infected cells, ac-
count for the role of follicular dendritic cells, cell-mediated immunity and also 
differential effects of antiretroviral drugs. 
Denise Kirschner has also assumed a prevalent role in the development 
of mathematical models of HIV infection. In 1993, Kirschner collaborated 
with Perelson and DeBoer [Perelson et al., 1993] to describe the dynamics of 
HIV infection of CD4 + T cells. This model describes the interactions between 
uninfected, latently and actively-infected T cell and virus populations. The 
model shows that HIV cytopathicity of peripheral CD4+ T cells and their 
precursors account for T cell depletion and explains low levels of infected cells 
and ongoing viral replication. In 1996, she developed a three-dimensional 
mathematical model that includes uninfected CD4+ T cells, infected CD4+ T 
cells and the virus [Kirschner, 1996]. A novel aspect of this model was the 
incorporation of a term that describes the T cell-mediated immune response 
against HIV mediated by CD4 + and CDS+ T cell populations. The term is 
a saturation term and represents the growth of both CD4+ and CDS+ T cell 
populations due to antigenic stimulation due to the presence of the virus. 
Antigen specificity is a key element to consider when incorporating the T 
cell-mediated immune response against HIV into a mathematical model [Altes 
et al., 2003]. With respect to cellular immune responses, only HIV -specific cells 
can respond to and mount effective anti-HIV attacks. Leon Cooper published 
the first mathematical model [Cooper, 19S6] to include the antigen-specific im-
mune response to HIV. The model considers the effect of the immune response 
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by including antigen-specific T and B cells and how they respond to HIV. The 
model accounts for interactions between antigen and antigen presenting cells, 
but assumes that they occur only between B cells and the virus. 1 All terms in 
the model are of constant, density-dependent or predator-prey forms. 
There are many other ordinary differential equation models of HIV infec-
tion that describe the interactions between immune cell populations and HIV. 
The development and use of these models was often for the same basic pur-
poses: to describe HIV infection as realistically as possible in an attempt to 
elucidate parameter values, explain the slow steady depletion of CD4+ T cells, 
or show the effects of treatment and treatment interruption [N otermans et al., 
1998; Komarova et al., 2003; Frost et al., 2002; Nowak & Bangham, 1996; Ding 
& Wu, 1999; Coffin, 1995; Borghans et al., 1999; Agrawal & Linderman, 1996; 
Altes et al., 2003; Bajaria et al., 2002; Blower, 2001; Hraba & Dolezal, 1996, 
Wodarz & Nowak, 2002; Nowak et al., 1997; Stafford et al., 1999; Witten & 
Perelson, 2004; Kirschner et al., 2000; Brandt et al., 2001; Perelson & Nelson, 
1999; Perelson, 2002]. 
The use of mathematical models to predict the effects of interrupting treat-
ment have become increasingly prevalent throughout the years [Adams et al., 
2004; Lori & Lisziewicz, 2001; De Jong et al., 1997]. Significantly, Bonhoeffer 
et al. [2000] developed a set of population dynamical models to study the 
effect of structured treatment interruptions on immune effector cells, latently-
infected cells and drug resistance. They use three versions of the same model 
to test the effects of treatment interruption on the model system. The terms 
in the model are of constant, density-dependent and predator-prey form. The 
1 B cells are one of three types of professional antigen presenting cell. 
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models show that if the effector cell population grows during the treatment 
phase of a treatment interruption regimen, then transient or sustained virus 
control can be achieved whereby the virological setpoint is reduced to lower 
levels. 
One of the purposes of this thesis is to examine the role of HIV -specific 
ens+ T cells in determining disease progression patterns with the aim of 
testing treatment interruption regimens. To do this, I explicitly include these 
cells as a variable population in a model of HIV immunopathogenesis. Studies 
show that the virus is controlled by the development of potent HIV-specific 
ens+ T cell responses [Musey et al., 1997; Kalams et al., 1999; nalod et al., 
1999]. Studies have also shown a direct correlation between that activities of 
HIV -specific ens+ T cells in the acute and chronic phases of infection, the 
virological setpoint level and subsequent disease progression patterns. HIV-
specific ens+ T cells kill virally-infected en4+ T cells, thereby constituting 
a source of depletion of both antigen-specific and non-specific en4+ T cells. 
Therefore, the explicit inclusion of a variable in a model that represents the 
HIV -specific ens+ T cell population can allow us to more precisely describe 
and examine the dynamical interactions between these and other HIV -specific 
T cell and virus populations. In turn, this will allow us to make accurate 
predictions about disease progression patterns and the effects of treatment 
and treatment interruptions with respect to the roles of HIV-specific T cells. 
In assigning meaning to model variables, I consider the fact that cellular 
immune responses against HIV are mediated by HIV -specific T cells: they 
are the only subset of T cells that have the ability to recognize the virus and 
mount effective anti-HIV responses. It is assumed that the immune response 
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is directly proportional to the number of HIV-specific (CD4+) T cells [Altes 
et al., 2003; Callaway et al., 1999; Kalams et al., 1999]. 
The novelty of the model arises from its description of the dynamical inter-
actions between HIV-specific T cell and virus populations. I explicitly include 
a variable that represents the CD8+ T cell population and make the T cell 
populations antigen specific. The model borrows from previously discussed 
conceptual ideas in deriving some of the terms. In the following chapter, I 
provide a description of the model variables and parameters. To assess the 
impact of including a variable that represents the HIV-specific CD8+ T cells 
on disease progression and attainment of the virological set point, I perform an 
analysis of the system when this population of cells is included both implicitly 
and explicitly in the system. 
Chapter 3 
Model of HIV 
Immunopathogenesis 
The model is four-dimensional and describes the dynamical interactions be-
tween three HIV-specific immune cell populations and HIV. The variables in 
the model are given in Table 3.1 and represent populations expressed as a 
concentration per microlitre (ul) of blood. 
Table 3.1: Description of model variables 
variable description units 
u uninfected HIV -specific CD4 + T cells cells/ul 
I infected HIV-specific CD4+ T cells cells/ul 
c HIV -specific CDS+ T cells cells/ul 
v plasma virus virionsjul 
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As previously described, I am interested in the activities of HIV -specific 
CDS+ T cells. Therefore, I express the variable populations as HIV-specific T 
cell populations. 
The parameters in the model are described in Table 3.2. The parameters 
are rates reported in the literature with exception of p. 
Table 3.2: Description of model parameters 
a1 = influx rate of uninfected HIV-specific en4+ T cells 
a2 = proliferation rate of uninfected HIV-specific en4+ T cells due to 
antigenic stimulation 
o: = saturation rate constant for uninfected HIV-specific en4+ T cells 
a3 = rate of encounters x the probability that uninfected HIV-specific en4+ 
T cells are converted to infected cells when an encounter occurs, U ---> V 
a4 = death rate of uninfected HIV-specific en4+ T cells 
b1 = rate at which infected HIV-specific en4+ T cells are killed by effector 
ens+ T cells (eTL) 
b2 = death rate of infected HIV -specific en4 + T cells 
C! = influx rate of HIV-specific ens+ T cells 
C2 = proliferation rate of HIV-specific ens+ T cells due to antigenic stimulation 
J = saturation rate constant for HIV-specific ens+ T cells 
CJ = death rate of HIV -specific ens+ T cells 
g1 = clearance rate of plasma virus 
h = the number of virions released per infected en4 + T cell 
p = conversion constant = the fraction of the total en4 + T 
cell population that is HIV-specific 
r = antiretroviral treatment 
p is a dimensionless parameter which converts the number of virions re-
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leased per infected HIV-specific CD4+ T cell to the number released per in-
fected CD4+ T cell. For simplicity, I assume that the ratio of HIV-specific 
CD4 + T cells to total CD4 + T cells is constant throughout infection. This 
accounts for the fact that virions can be produced by all infected CD4+ T 
cells and not just infected HIV-specific CD4+ T cells. 
The model is as follows: 
dU a2UV (3.0.1a) dt a1 + V- a3UV- a4U a+ 
di 
a3UV- b1IC- b2I (3.0.1b) dt 
dC c2CV (3.0.1c) dt c1 +-- -c3C o+V 
dV 1 (3.0.1d) -
--1 b2phl - 91 v dt r+ 
3.1 Description of Terms 
The terms in the model are of constant, saturation, density-dependent or 
predator-prey form and are described in the following subsections. 
3.1.1 Equation 1 
(3.0.1a) is composed of four terms: two terms to account for growth and two 
terms to account for loss of the uninfected HIV-specific CD4+ T cells. The 
term a 1 is a rate constant and represents the influx of these cells, assumedly 
of thymic origin. The second term represents the production of HIV-specific 
CD4+ T cells due to antigenic stimulation by the virus where a2 is the prolifer-
ation rate constant. Proliferation is the dominant growth factor for this subset 
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of cells. a represents the saturation constant whereby there is some maximum 
rate of proliferation (a2U) when all the antigenically stimulated cells are satu-
rated: an increase in antigenic stimulation will not further increase the growth 
rate of the infected cell population. The third term in the equation represents 
the switch in status from uninfected to infected which is dependent on V. 
a3 is the infection rate constant, and infection is assumed to occur at a rate 
proportional to the density of virions and uninfected target cells. a4 is the 
death rate constant. Death is assumed to be proportional to the density of 
uninfected HIV -specific CD4 + T cells. 
3.1.2 Equation 2 
In accordance with (3.0.la), the first term in (3.0.1b) represents the growth 
of infected HIV-specific CD4+ T cells where a3 is the infection rate constant. 
Infection is assumed to occur at a rate proportional to the product of the 
density of virions and uninfected target cells. The second term represents 
the loss or removal of infected HIV-specific CD4+ T cells due to antiviral 
effects of HIV -specific CDS+ T cells. The constant b1 is the removal rate. 
Removal is assumed to occur at a rate proportional to the product of the 
density of infected HIV-specific CD4+ T cells and HIV-specific CDS+ T cells. 
These cells are assumed to impose various antiviral effects on infected cells; the 
end product being their removal from the system. The third term represents 
natural death of infected cells where b2 is the death rate. This death rate is 
assumed to be proportional to the density of infected HIV-specific CD4+ T 
cells, and is larger than that of the uninfected cells. 
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3.1.3 Equation 3 
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(3.0.lc) is much like (3.0.la) but comprises only three terms: two to account 
for growth and one to account for loss of HIV -specific ens+ T cells. The first 
term in (3.0.1c) represents the influx rate of HIV-specific ens+ T cells, also 
of thymic origin. The second term represents the production of HIV-specific 
ens+ T cells due to antigenic stimulation, where C2 is the proliferation rate 
constant. 6 represents the saturation rate constant whereby the rate becomes 
saturated at high virus concentrations. Proliferation is assumed to occur at 
a rate proportional to the product of the density of ens+ T cells and the 
virus at time t, and will only result in a rise in the HIV -specific ens+ T cell 
population up to a certain point. The third term in (3.0.1c) represents the 
natural loss of HIV -specific ens+ T cells where the constant C3 represents the 
death rate. Death is proportional to the population of HIV-specific ens+ T 
cells itself. 
3.1.4 Equation 4 
(3.0.1d) comprises two terms to account for growth and loss of the virus pop-
ulation. The growth term assumes that the production of new virions is de-
pendent on the infected cell population. The rate at which new virions are 
produced (enter the system) is proportional to the HIV-specific eD4+ T cell 
population in that when an infected HIV -specific cell dies, it releases a num-
ber of new infectious virions into the surrounding environment. However, the 
overall production of new virions will be dependent on the total infected cell 
population, which is assumed to be proportional to the infected HIV -specific 
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CD4+ T cell population at any time t. We can simply multiply the rate at 
which plasma virions are produced in the HIV-specific population (b2h) by p 
to obtain the rate of virions released by the total infected CD4 + T cell popu-
lation. The loss term represents the natural clearance of plasma virions where 
91 is the clearance rate. 
Antiretroviral treatment is incorporated into the model in the form of a 
single parameter (r) that modifies the production rate of the new virions. 
Protease inhibitors greatly decrease the production of new infectious virus by 
interfering with the infection process. The more potent or efficient the protease 
inhibitor is, which is dependent on dosage and timing, the greater the value of 
the parameter r. I assume that the protease inhibitor does not decrease the 
rate of viral production by 100% but by approximately 99% (approximately 
a 2-log drop in virus load). In chapter 4, I examine the effects of varying the 
value of r using bifurcation analysis. 
3.2 Assigning values to the parameters 
Typically, in a lower order system of equations, the system would be solved 
prior to inputting numerical parameter values to obtain general expressions for 
the fixed point solutions of the system. These general expressions allow the 
stipulation of conditions whereby if a parameter lies in a certain range, then 
certain behaviours are elicited by the system. However, in higher order sys-
tems, such as the model system in this thesis, these general expressions can be-
come quite cumbersome making it virtually impossible to stipulate parameter 
conditions. This problem is circumvented by inputting numerical parameter 
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values reported from the literature into the model equations prior to solving 
for fixed points. In doing so, instead of general expressions for fixed points, 
numerical values are obtained. Table 3.3 summarizes the selected numerical 
parameter values with literature sources. 
Table 3.3: Parameter values, units and sources 
parameter value units source 
a1 10 cells Kirschner & Perelson, 1995 ulxday 
a2 0.05 1 Perelson et al., 1999 day 
a 1000 virions Kirschner, 1996 _u_l_ 
a3 0.001 ul Kirschner et al., 2000 virionsxday 
a4 0.02 1 Kirschner & Perelson, 1995 day 
b1 0.05 ul Bonhoeffer et al., 2000 cellsxday 
b2 0.5 1 Essunger & Perelson, 1994 day 
c1 1 cells Adams et al., 2004 ulxday 
c2 0.05 1 Bonhoeffer et al., 2000 day 
CJ 0.1 1 Bonhoeffer et al., 2000 day 
8 1000 virions Kirschner, 1996 _u_l_ 
91 13 1 Callaway & Perelson, 2002 day 
h 600 virions Essunger & Perelson, 1994 CD4 T cell 
p 100 CD4 Douek et al., 2000 HIV-specific CD4 
These numerical parameter values are first input into the equations and 
then the protocol outlined in Chapter 2 is used to analyze the model system. 
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3.3 Omission of the C equation 
The best way to determine the effects of explicitly including the C equation 
(3.0.1c) in the model is to omit it from the original system and perform an 
analysis of the remaining three-dimensional system where the activities of the 
CDS+ T cells are implicitly characterized. In doing so, I can test whether 
the three-dimensional system, which excludes this equation, yields different 
predicted behaviour from the four-dimensional system. 
The three-dimensional system is identical to the four-dimensional system 
with the exception of the I equation (3.0.1b): it no longer contains a term 
that accounts for the loss of infected cells from an extraneous source. 
The three-dimensional model is as follows: 
dU a2UV (3.3.1a) 
dt a1 + V - a3UV - a4U a+ 
dl 
a3UV- b2I (3.3.1b) 
dt 
dV 1 (3.3.1c) 
dt --b2hpl - 91 v, r+l 
where the parameters are as described in Tables 3.2 and 3.3. 
3.3.1 Fixed points and stabilities 
The fixed points (U,I, V) are found by setting the right-hand-sides of equa-
tions (3.3.1) equal to zero and solving the algebraic equations. The numerical 
parameter values (Table 3.3) are substituted into the model to obtain the 
following three nontrivial fixed points, 
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(U,l, V) - (500, 0, 0), 
- (0.22, -0.43, -998.94), 
(0.22, 20.01, 46182.79). 
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(3.3.2a) 
(3.3.2b) 
(3.3.2c) 
In the absence of treatment, the model predicts the existence of two equilib-
rium states (3.3.2a) and (3.3.2b) associated with viral clearance from the host. 
(3.3.2a) shows that the uninfected cell population is healthy but susceptible 
to infection. However, the infected cell and virus populations have died out. 
Similarly in (3.3.2b ), the uninfected cell population is healthy and small, but 
the infected cell and virus populations have died out. HIV is never completely 
eradicated from the host. Therefore, biologically, these equilibrium points are 
unrealistic in that negative values cannot be present. However, fixed point 
(3.3.2c) comprises three positive values for U, I and V. This means that the 
host is living with the virus. More specifically, the fixed point that corresponds 
to this state implies that the host is living with the virus but is not controlling 
the virus. This is based on the fact that the viral setpoint is 46182.79. (Refer 
to Chapter 1.) 
The eigenvalues for fixed points (3.3.2a) and (3.3.2b) are 
>.1,2,3 = -0.02, 115.88, -129.38, 
and 
>.1,2,3 = -89.09, 14.72 + 55.03i, 14.72 - 55.03i, 
indicating that (3.3.2a) is an unstable saddle point and (3.3.2b) is an unstable 
spiral saddle point. This is due to the positive real-valued components of each 
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set of eigenvalues. The third fixed point (3.3.2c) is stable by its eigenvalues 
.A1,2,3 = -46.35, -0.51, -12.80. 
This is due to the negative real-valued eigenvalues. 
Thus, for the chosen parameter set, the three-dimensional model system 
predicts the existence of three fixed points: two of which are unstable and one 
of which is stable and biologically relevant. Based on numerical simulations, no 
other stable phenomena were observed. The remainder of this section focuses 
solely on the stable fixed point (3.3.2c) since the system moves from an initial 
state (U0 , 10 , V0 ) toward the stable fixed point and away from the other fixed 
points based on these simulations. 
3.3.2 Location and nature of fixed point 
The location and stability of the stable fixed point in three-dimensional space 
can be illustrated by generating a three-dimensional phase diagram as shown 
in Figure 3.1. To reiterate, the fixed point is 
(U, I, V) = (0.22, 20.01, 46182.79) 
and has eigenvalues 
-A1,2,3 = -46.35, -0.51, -12.80. 
The eigenvalues tell us not only about the stability of the fixed point, but 
the nature. Since the eigenvalues comprise three real-valued components, the 
fixed point is a node. In Figure 3.1, three orbits are shown originating from 
three different, randomly selected initial conditions (U0 , 10 , Vo) = (1, 5, 50), 
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The equilibrium state corresponds to the fixed point with coordinates (U, I, V). 
The acute phase of infection is generally marked by transient rapid changes 
in immune cell and virus populations as the variable populations approach the 
equilibrium state. The chronic phase of infection is marked by the arrival 
at the equilibrium state. Once the equilibrium state is reached, the variable 
populations (as a system) stay there unless an external influence, such as 
treatment, displaces them or the individual moves out of the chronic phase 
and into AIDS. The model does not attempt to predict the transition to an 
AIDS state. Since I am interested in the dynamical interactions during the 
chronic phase of infection and am investigating the changes in the variables 
during treatment interruption, it is not noteworthy that the model does not 
predict an AIDS state. This is discussed further in Chapter 6. As described 
in the previous section, perturbation of the equilibrium state with treatment 
does not cause the system to switch to another equilibrium state: it returns 
to the original one. This is because there is only one stable equilibrium state 
predicted by the model for the chosen parameter set. For each two-dimensional 
time-series plot, the x-axis is the time (days), and the y-axis is the number 
of T cells in each respective T cell population and the virus load at time t. 
The paths traced out by the variable trajectories are analogous to HIV disease 
progression. When the trajectories plateau, they have reached the equilibrium 
state. 
To plot the solutions, the parameter set (Table 3.3) and a set of initial 
conditions are required as input into the system of equations. I chose the 
initial condition (U0 , 10 , Vo) = (1, 1, 50) as it was used previously as an initial 
condition for the phase diagram (Figure 3.1). 
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tions, the virus population (V) immediately begins to grow directly to reach 
a high off-treatment equilibrium level (setpoint) (V = 4.66). Subsequently, 
the uninfected HIV-specific CD4+ T cell population grows due to antigenic 
stimulation and subsequently decays due to infection by the virus. The in-
fected HIV-specific CD4+ T cell population grows slowly as the uninfected 
cell population decays until both populations reach the equilibrium state. Af-
ter approximately 8 days, all three populations have reached the equilibrium 
state. No oscillations are predicted. 
Clinical trends in changing T cell counts and virus loads in early infection 
are in agreement with this result. However, in a clinical setting the equilibrium 
state never occurs as early as 8 days post-infection. It usually takes up to 
one year for an individual to reach this state and enter the chronic phase of 
infection. I address this in Chapter 4. 
3.4.1 Fixed points and stability with treatment 
Now that it is known how the system behaves off-treatment, I want to know 
how it behaves on-treatment. This is done by direct inspection of fixed points 
and eigenvalues generated for progressively higher parameter values and also 
using bifurcation analysis. Changing the value of r is analogous to examining 
the effects of changing the dosage or potency of treatment. How well treatment 
lowers the viral setpoint (V) will depend on how much it reduces the viral 
production rate. 
For each value of r, there is one corresponding stable fixed point. Ulti-
mately, I set a value for the treatment parameter r based on the how effec-
tively it reduces the viral production rate to lower the viral setpoint to an 
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undetectable level. I am aiming to use a value of r that reduces the viral 
setpoint to one percent of its non-treatment value ("a 2-log drop"), as this is 
how treatment efficacy is measured. By clinical standards, a viral load of less 
than 50 HIV RNA copies per cubic ml plasma or a viral load of less than 398 
HIV RNA copies per cubic ml plasma are considered undetectable, depending 
on the sensitivity of the RNA detection assay used. This will be reflected in 
the value obtained for V in the fixed point. 
Table 3.4 shows the respective changes in each of U, 1 and Vas the treat-
ment parameter r is assigned progressively higher values. Also shown are the 
changes in eigenvalues and stabilities of each fixed point. 
Table 3.4: The effects of assigning sequentially higher values to r 
r u 1 v eigenvalues I stability I 
0 0.22 20.02 46182.79 -46.35,-0.51,-12.80 s 
100 21.88 19.81 452.55 -0.22+0.04i,-0.22-0.04i,-13.52 s 
500 108.55 16.42 75.64 -0.04+0.18i,-0.04-0.18i,-13.50 s 
1000 216.88 11.90 27.44 -0.02+0.11i,-0.02-0.11i,-13.50 s 
1500 325.22 7.35 11.31 -0.02+0.07i,-0.02-0.07i,-13.50 s 
2000 433.55 2.80 3.23 -0.01+0.04i,-0.01-0.04i,-13.50 s 
2200 476.88 0.94 1.02 -0.01 +0.02i,-0.01-0.02i,-13.50 s 
2307 500 0 0 -0.02,-0.000064,-13.50 s 
For progressively higher values of r, there are more uninfected cells at 
equilibrium as indicated by the changes in the value of U. For progressively 
higher values of r, there are fewer infected cells and lower viral set points at 
equilibrium as indicated by changes in the values of 1 and V. 
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The eigenvalues associated with each fixed point change accordingly as the 
value of r is varied. When r = 0, they indicate that the fixed point is a sta-
ble node, as previously established. For values of r = 100 to r = 2000, the 
eigenvalues comprise both (negative) real-valued and complex parts indicat-
ing that the corresponding fixed points are asymptotically stable spiral node 
points. Eigenvalues with complex parts cause oscillatory effects in the system 
as illustrated in Figure 3.3. When the value of r is increased to r = 2307, 
the eigenvalues contain a near zero value indicating a switch in stability at 
this point. I discuss the switch of stability in the system when the bifurca-
tion analysis is done in subsection 3.4.3. The changes in eigenvalues and the 
induction of oscillations can be visualized by plotting the system solutions for 
various values of r in time series plots. 
3.4.2 Solving the system with treatment 
Figure 3.3 illustrates the effects on the solutions when the value of r is assigned 
progressively higher values. Since treatment regimens can be initiated at any 
time point post-infection (usually following acute phase resolution), treatment 
is initiated on day 30. 
Figure 3.3 shows that for progressively higher r values, the viral produc-
tion rate progressively decreases to reflect progressively 'preferable' fixed point 
values which are analogous to disease equilibrium states. Treatment induces 
damped oscillations in all cases indicating transient instability in the system. 
In general, as the value of r is increased, the uninfected cell population grows 
to successively higher peak values, and the infected cell and virus populations 
decay to successively lower trough values. In addition, the oscillations increase 
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in period and amplitude as the value of r is increased, and are not sustained. 
Thus, the higher the value of r, the longer it takes for the system to reach the 
equilibrium state. According to Table 3.4 and Figure 3.3, a value of r = 100 
reduces the virus load by 2-logarithms. This is equivalent to a 99% reduction 
in the viral production rate. 
Figure 3.3( d) demonstrates that as the value of r increases, I and V decay 
to reach such low levels that they almost become extinct. This is indicated by 
the roughness in the variable trajectories that trough around day 250. This 
roughness is attributable to the fact that the values for I and V during this 
period are minute. Importantly, this activity also indicates that there exists a 
critical value of r whereby if its value surpasses some critical value, the I and 
V populations will become extinct. This can be confirmed using bifurcation 
theory. 
As far as visualizing system changes as the parameter r is varied, time series 
plots are useful in determing time-associated changes in the system. However, 
a more complete way to visualize the changes in the behaviour of the system 
as the parameter r is varied is to use bifurcation diagrams. 
3.4.3 Bifurcation analysis 
Figures 3.4(a), (b) and (c) show how U, I and V change as the parameter r is 
varied, respectively. Each diagram shows the respective fixed point value at a 
particular value of r. 
Figure 3.4 confirms that the fixed points are stable for a large range of r 
values. At values of r < 2307, the fixed points are stable with positive coordi-
nates. The value of r is directly related to U and indirectly related to I and 
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Figure 3.4: Bifurcation diagrams showing changes in U, I and Vas r is varied. 
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V: larger corresponds to large U and small I and V. A transcritical bifurca-
tion occurs at r = 2307. At the bifurcation point, the fixed points exchange 
stability where the original stable fixed point solution with positive fixed point 
coordinates becomes unstable, and the unstable fixed point (3.3.2a) becomes 
stable. This fixed point (U, I, V) = (500, 0, 0) remains stable for all values 
r ~ 2307. When r = 2307, the viral production rate is reduced by 99.96%. 
This means that treatment drives the infected cell and virus populations to 
extinction when it reduces the viral production rate by at least 99.96%. 
At these high treatment efficacies where the virus production rate is re-
duced by at least 99.96%, the turnover rate of the virus is modified such that 
the loss rates of virus from the system exceed the production rate. Since treat-
ment reduces the production rate of the virus in the model, it makes sense that 
increasing the effectiveness of treatment to a point below 100% will reduce the 
viral production rate below the virus removal rates to result in the virus-free 
equilibrium: a 0% production rate is not required to bring the bring the virus 
population to 0 as long as the overall loss of virus from the system is greater 
than the gain. 
The fact that this can theoretically happen does not mean that it does in 
reality. In fact, in reality, protease inhibitors do not act to reduce the viral 
production rate by virtually 100% (99.96%) but by approximately 99%. The 
model simply predicts that if drugs were in fact efficient enough to reduce 
the viral production rate by virtually 100% (99.96%), then the virus would be 
eradicated from the system because the loss rates of the virus would exceed 
the production rate. 
Studies show that this prediction can be clinically confirmed. CD4+ T cell 
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depletion has been suggested as a way to eliminate the virus from the system 
[Tepic, 2004]. By suddenly removing (surgically depleting) a fraction of CD4+ 
T cells, the system is perturbed such that the removal rate or death rate of the 
CD4+ T cells changes to increase past some critical value [DeBoer & Boucher, 
1996]. Thus, the rate at which CD4+ T cells die is altered (increased) to reduce 
the susceptible pool of cells to allow the system to clear the virus. 
Therefore, even though the model allows for the theoretical existence of a 
virus-free equilibrium state induced by treatment, this state is never attained 
in reality because treatment is never this efficient. 
Bifurcation analysis confirms the existence of a disease equilibrium state 
whereby the equilibrium virus load successively decreases as the efficacy of 
treatment is increased. It also confirms the existence of a virus-free equilibrium 
at near 100% treatment efficacy. Since the disease equilibrium state can be 
perturbed using any given treatment efficacy (r), a value of r = 100 is selected 
to test treatment interruption regimens because it mimics the effects of efficient 
protease inhibitors when input into the model. That is, it reduces the viral 
setpoint by 2-logs. 
3.4.4 Treatment interruption 
According to Table 3.4, when the treatment parameter has a value of r = 100, 
the viral setpoint is reduced by 2-logs to a low detectable level (V = 452.55) 
by clinical standards by reducing the viral production rate by 99%. The fixed 
point associated with the treatment parameter with value r = 100 is 
(U, I, V) = (21.88, 19.81, 452.55), 
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30 day off-treatment period followed directly by a 30-day on-treatment period 
which is subsequently interrupted indefinitely. Following the perturbation of 
the system with a single treatment phase (30 days), the system returns to 
its original pre-treatment equilibrium state. Figure 3.5(b) shows that follow-
ing two perturbations with treatment the system again returns to its original 
pre-treatment equilibrium state. The behaviours of the variable trajectories 
are identical for both treatment interruption regimens in 3.5(a) and (b). The 
uninfected cell population grows and the infected cell and virus populations 
decay when treatment is on. But, the number of interruptions does not appear 
to affect the end result which is the arrival at the pre-treatment equilibrium 
state. To determine whether durations of treatment or interruption phases 
would cause the same result, we modified both as seen in Figure 3.5(c). Even 
when the durations of the on-treatment and off-treatment phases are modified, 
the outcome is the same as for the other regimens: the system returns to its 
original pre-treatment state. The only time the system does not return to this 
state is when treatment is kept on as seen in Figure 3.6. In this case, the 
system returns to the original on-treatment equilibrium state. The conclusion 
is the same: whether treatment is kept on or taken off, what happens in the 
interim in a treatment interruption regimen does not affect the re-arrival at 
either the off or on-treatment equilibrium states. This was a predictable result 
in that there is only single stable fixed point: only one place to go. 
In summary, the three-dimensional model predicts that following a very 
short acute phase, the system solutions reach an equilibrium state. The fixed 
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kept on following a treatment interruption, the off-treatment equilibrium state 
reappears, according to three-dimensional model predictions. 
Now that the system behaviour without the C equation is known, the be-
haviour of the complete four-dimensional system can be examined following 
the same protocol. With the inclusion of C as a variable, which again repre-
sents the HIV -specific CDS+ T cell population, I will be able to investigate 
how the HIV -specific CDS+ T cell population changes in the context of treat-
ment interruptions. I will therefore be able to confirm whether treatment 
interruptions can be used to boost these responses during the off-treatment 
phases. 
Chapter 4 
The model 
The four-dimensional model is as follows: 
dU a2UV (4.0.1a) dt a1 + V- a3UV- a4U a+ 
dl 
a3UV- b1IC- b2I (4.0.1b) dt 
dC c2CV (4.0.1c) dt - c1 + -- -c3C 8+V 
dV 1 (4.0.1d) dt --b2hpl - 91 v. r+1 
4.1 Fixed points and stabilities 
The fixed points (U, I, C, V) are found by setting the right-hand-sides of the 
equations ( 4.0.1) equal to zero and solving the resultant algebraic equations. 
The numerical parameter values from Table 3.3 were substituted into the equa-
tions to obtain the following four fixed points, 
60 
CHAPTER 4. THE MODEL 
(U,l,C, V) (500, 0, 10, 0), 
(0.22, -0.43, 0.02, -998.94), 
- ( -4.98, -0.83, -239.94, -1923.06), 
(0.63, 6.93, 18.89, 16003.28). 
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(4.1.1a) 
(4.1.1b) 
(4.1.1c) 
(4.1.1d) 
The four-dimensional model predicts the existence of two equilibrium states 
(4.1.1a) and (4.1.1b) associated with viral clearance from the host and an 
equilibrium state ( 4.4.1c) associated with the death of the host. The model 
also predicts an equilibrium state (4.1.1d) where the host is living with the 
virus. The fixed point that corresponds to this state comprises four positive 
coordinates (U, I, C, V) whereby the host is controlling the virus reasonably 
well. This is based on the fact that the viral setpoint is 16003.28. (Refer to 
Chapter 1.) 
The eigenvalues for fixed points (4.1.1a), (4.1.1b) and (4.1.1c) are 
>11,2,3,4 = -0.02, -0.10, 115.62, -129.62, 
>.1,2,3,4 = 14.70 + 54.96i, 14.70- 54.96i, -88.95, -47.14, 
and 
>.1,2,3,4 = 3.51 + 5.58i, 3.51- 5.58i, -6.63, 0.13 
indicating that each of these fixed points is unstable where ( 4.1.1a) is an un-
stable saddle point and ( 4.1.1 b) and ( 4.4.1c) are unstable spiral saddle points. 
However, the fourth fixed point (4.1.1d) is stable by its eigenvalues 
>.1,2,3,4 = -19.24, -9.55, -1.63, -0.05, 
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which indicate that it is a stable node. 
Thus, the four-dimensional model predicts the existence of four equilibrium 
states; three of which are unstable and one of which is stable and biologically 
relevant. The fact that there are negative values in fixed points ( 4.1.1a) and 
(4.1.1b) implies a non-realisitic state in that HIV is never entirely cleared from 
the host. This is not a problem since these fixed points are unstable. 
The remainder of this section focuses on the stable fixed point ( 4.0.1d) 
since the system moves from an initial state (U0 , 10 , C0 , Vo) toward the stable 
fixed point and away from the unstable fixed points. Although global stability 
of the stable fixed point has not been demonstrated, numerical simulations 
have not demonstrated the existence of more complicated behaviour. 
4.1.1 Quantitative comparison of fixed points with and 
without C equation 
Recall that the stable fixed point coordinates for U, I, (C) and V in the three 
and four-dimensional systems are 
(U, 1, V) = (0.22, 20.01, 46182.79) 
and 
(U, 1, C, V) = (0.63, 6.93, 18.89, 16003.28), 
respectively. It appears upon direct inspection of the fixed point values that it 
is "preferable" to explicitly include the C equation in the system as it appears 
to subject "positive pressure" on the system: it decreases the viral setpoint 
(V) and the infected cell population at equilibrium (7) and increases the un-
infected cell population at equilibrium (U). (An HIV-infected individual with 
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a virus load of 4.2 would be considered to be controlling the virus better than 
an individual with a virus load of 4.66.) Specifically, when the C equation is 
explicitly included in the model there is a larger predicted population of un-
infected cells (three times as large), a smaller predicted population of infected 
cells (three times as small) and a smaller predicted virus population (three 
times as small) at off-treatment equilibrium. Therefore, the explicit inclusion 
of the C equation as a variable in the system renders the fixed point solution 
more desirable and also realistic because HIV -specific CD8+ T cells in fact do 
impose antiviral pressure on the virus to reduce the virus load. I make further 
comparisons between the three and four-dimensional systems upon further 
analysis of the four-dimensional system. 
As previously discussed, phase diagrams are useful for visualizing the loca-
tions and stabilities of stable fixed points. Figure 4.1 shows the location and 
stability of the stable fixed point 
(U, I, C, V) = (0.63, 6.93, 18.89, 16003.28) 
in three-dimensional phase space. To reiterate, its eigenvalues are 
.A1,2,3,4 = -19.24, -9.55, -1.63, -0.05 
and tell us that this fixed point is a stable node, as depicted in the phase 
diagram. 
Each of the three orbits originate from an initial condition (U0 , ! 0 , C0 , V0 ) 
and traces out a distinct path in phase space to eventually arrive at the stable 
fixed point. The initial conditions were randomly selected to represent the 
number ofT cells and amount of virus that an HIV-infected individual starts 
off with. The fact that we can randomly assign initial conditions means that 
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virus in the first few hours of infection. As the infection progresses past day 
1, each variable population changes more slowly. (Refer to Figure 4.2.) As 
a result of the expanding HIV-specific CDS+ T cell population and the lack 
of susceptible uninfected cells, the virus population continues to decay which 
in turn spurs the decay of the infected cell population and re-establishment 
of a small uninfected cell population. After approximately 80 days, all four 
populations have reached the equilibrium state as seen in Figure 4.2. 
4.2.1 Comparison of time series plots for three and four-
dimensional systems 
If we compare the three and four-dimensional times series plots (Figure 4.4) 
we can see that it takes a longer period of time for all populations to reach 
the equilibrium state when C is explicitly included in the system as a variable 
(Figure 4.4b). 
This result also lends to the realism of the four-dimensional system. It is a 
more realistic portrayal of the chronology of the progression through the acute 
and chronic phases of infection. 
It is important to bear in mind that the model describes the activities of 
HIV -specific T cell populations, therefore it is possible that the rapid pro-
gression to the equilibrium state is characteristic of the specific interactions 
between HIV-specific populations and HIV. The infection rate of HIV-specific 
T cells is the highest found reported value (a3 = 0.001) to account for the fact 
that these cells are preferentially infected and depleted. Also, the dynamics are 
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Table 4.1: The effects of assigning sequentially higher values tor 
r I v eigenvalues I stability I 
0 0.63 6.93 18.89 16003.28 -19.24,-9.55,-1.63,-0.05 s 
100 45.81 9.05 10.94 206.83 -14.06,-0.10+0.43i,-0.10-0.43i,-0.09 s 
500 218.55 5.88 10.13 27.07 -14.01,-0.02+0.16i,-0.02-0.16i,-0.10 s 
800 347.89 3.19 10.05 9.20 -14.00,-0.01 +0.09i,-0.01-0.09i,-0.10 s 
1000 434.11 1.39 10.02 3.19 -14.00,-0.01 +0.05i,-0.01-0.05i,-0.10 s 
1153 500.07 -0.0014 10.00 -0.0028 -14.00,-0.03,0.00012,-0.10 s 
For progressively higher values of r, there are more uninfected cells at 
equilibrium, as indicated by changes in the value of U and progressively fewer 
infected cells and virus at equilibrium, as indicated by changes in the values 
of I and V. The number of HIV-specific ens+ T cells at equilibrium changes 
as the value of r is increased from 0 to 100, as indicated by the change in the 
value of C. But for values of r when 100 < r < 1000, C does not change 
considerably. Even when the value r is increased from 1000 to 1153, causing 
the infected cell and virus populations to become extinct, C does not change 
much. This implies that C is less sensitive to changes not only in r, but to 
subsequent changes in the other variables. HIV -specific CDS+ T cells typically 
respond quickly to changes in virus load, but these changes can vary among 
HIV-infected individuals depending on the quality of the HIV-specific ens+ 
T cells that respond. This result will further be discussed in section 4.4.1 and 
Chapters 6 and 7. 
The eigenvalues associated with each fixed point change accordingly as the 
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value of r is varied. For 0 < r < 100, the corresponding fixed points are stable 
nodes as indicated by the negative real-valued eigenvalues. For 100 < r < 
1000, the eigenvalues comprise both (negative) real-valued and complex parts 
indicating that the corresponding fixed points are asymptotically stable spiral 
node points. Eigenvalues with complex parts cause oscillatory effects in the 
system. When the value of r is increased to r = 1153, the eigenvalues contain 
a near zero value indicating a switch in stability of the system. I discuss the 
switch of stability in the system when the bifurcation analysis is done in the 
following subsection ( 4.3.1). 
We can examine the behaviours of the variables as they change with respect 
to time at any stage of disease progression (not just at the equilibrium state) 
by generating time series plots. The plots confirm the induction of unsustained 
oscillations as the value of r is varied. 
Figure 4.5 illustrates the effects on the system solutions as r is assigned 
progressively higher values. Treatment is initiated post-resolution of acute 
infection (day 100). As the value of r is increased, the corresponding fixed 
points reflect preferable disease equilibrium states as indicated by the fixed 
point values. Treatment (r > 0) induces unsustained oscillations in all cases. 
In general, as the value of r is increased, the uninfected cell population grows 
to successively higher peak values, and the infected cell and virus populations 
decay to successively lower trough values. In addition, the oscillations increase 
in period and amplitude as the value of r is increased. Thus the higher the 
value of r, the longer it takes for the system to reach the equilibrium states 
with corresponding successively lower viral setpoints. These results confirm 
that the actions of the treatment parameter on the system realistically mimics 
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the actions of protease inhibitors on the virus. 
To better visualize long-term system changes as the parameter r is varied, 
we generate bifurcation diagrams. Again, this provides a complete picture of 
all possible states of the system for a large range of r values. 
4.3.1 Bifurcation analysis - varying r 
Figure 4.6 shows how U, 1, C and V change as the parameter r is varied, and 
confirms that the fixed points are stable for a large range of r values. When 
0 < r < 1153, the fixed points are stable and positive. 
There is a direct relationship between rand U and an indirect relationship 
between r and 1 and V: large r corresponds to large U and small 7, C and V. 
A transcritical bifurcation occurs at r = 1153 as seen more clearly in Figure 
4.7. 
At the bifurcation point, the system undergoes an exchange of stability. 
The original stable fixed point solution with positive coordinates becomes un-
stable and the unstable fixed point (4.4.1a) with U > 0 and C > 0 and 
1 = 0 and V = 0 becomes stable at the bifurcation point. The fixed point 
(U, 1, C, V) = (500, 0, 10, 0) remains stable for all r ~ 1153. When r = 1153, 
the viral production rate is reduced by 99.91%. This means that treatment 
drives the infected cell and virus populations to extinction when it reduces the 
viral production rate by at least 99.91%. Thus, for very high treatment effica-
cies (virus production rate reduced by at least 99.91%), the model predicts the 
existence of a virus-free equilibrium state. As previously described in section 
3.4.3, this prediction is theoretical. Treatment will never be this efficient in 
reality, and if it was, it would probably kill the patient due to high toxicity. 
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Figure 4.6: Bifurcation diagrams of U, I, C and V perspectives showing tran-
scritical bifurcation at r = 1153. 
The model simply predicts that if treatment does reduce the viral production 
rate below some threshold, the virus is eliminated from the system based on 
the fact that the death rates are higher than the production rates at these 
high treatment values. 
Thus, bifurcation diagrams confirm analytical findings that demonstrate 
an inverse relationship between rand V, and shows that there is an exchange 
of stability at the bifurcation valuer= 1153. Treatment must reduce the viral 
production rate by more than 99.9% in order for this switch to occur, but we 
do not need 0% production to eradicate the virus as long as the loss rates 
exceed the production rate. 
By comparing the bifurcation diagrams for the three and four-dimensional 
systems as the treatment parameter r is varied (Figure 4.8), we can see that 
the bifurcation value for the three-dimensional system occurs at a larger value 
for r. To reiterate, a transcritical bifurcation occurs at r = 2307 in the three-
dimensional system and at r = 1153 in the four-dimensional system. 
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Figure 4. 7: Bifurcation diagram - changes in V as r is varied. A transcritical 
bifurcation occurs at r = 1153. 
This means that when C is explicitly included in the model as a variable, 
the treatment parameter does not need to be as large as it does when it is 
excluded to impose the same effects on the system. Therefore, bifurcation 
diagrams confirm that the explicit inclusion of C imposes pressure on the 
system whereby treatment need not be as potent to suppress the virus to 
undetectable levels (lower viral set point V). This result is promising with 
respect to the predicted virus-free equilibrium state. The fact that treatment 
induces a virus-free equilibrium state by reducing the viral production rate less 
than it is reduced in the three-dimensional model when an additional variable 
that removes the virus from the system is explicitly included supports the fact 
that the model is portraying a valid picture of the effects of treatment. The 
number of ways for the virus to be removed from the system is larger and thus 
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(a) 3-D, Bifurcation at r = 2307 (b) 4-D, Bifurcation at r = 1153 
Figure 4.8: Comparison of bifurcation diagrams for three and four-dimensional 
systems - changes in V as r is varied. 
the production rate of virus does not need to be reduced as much for this rate 
to be less than the death (virus removal) rates. 
4.4 Treatment interruption 
To examine the effects of treatment interruption on the system solutions we 
need to fix the value of r where r > 0. We select a value that is not too 
close to the bifurcation value and that reduces V to an undetectable level. 
According to Table 4.1 and Figure 4.5, when the treatment parameter has 
a value of r = 100, the viral setpoint is reduced to what is considered an 
undetectable level (V =206.83) by clinical standards (based on the less sensitive 
RNA detection assay) by reducing the viral production rate by 98.7%. To 
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reiterate, the stable fixed point associated with the treatment parameter when 
r = 100 is 
(U, 1, C, V) = (45.81, 9.05, 10.94, 206.83) 
with eigenvalues 
,\1,2,3,4 = -14.06,-0.10 + 0.43i, -0.10- 0.43i, -0.09. 
Figure 4. 9 is the phase diagram when r = 100 and confirms the location and 
stability of the stable fixed point. The fixed point is an asymptotically stable 
spiral node. Recall that the time series plot for r = 100 revealed the induction 
of oscillations. These oscillations are analogous to the spiralling effect in the 
phase diagram and are predictable by the natures of the eigenvalues. 
To demonstrate the effects of treatment interruption using time series plots, 
we solve the system by intermittantly assigning treatment parameter values 
r = 0 (off-treatment) and r = 100 (on-treatment) using a piecewise linear 
function. 
Figure 4.10 shows the time series plots for three different treatment inter-
ruption regimens. In all cases, treatment is initiated 100 days post-infection. 
The first regimen is a 100 day-off, 100 day-on, off regimen. The second is a 
100 day-off, 100 day-on, 100 day-off, 100 day-on, off regimen, and the third is 
a 100 day-off, 100 day-on, 200 day-off, 90 day-on, off regimen. Figure 4.10(a) 
shows that when treatment is withdrawn after 100 days, the variable trajecto-
ries return to the pre-treatment equilibrium state. This means that following 
a perturbation of the system with a single treatment phase (100 days), the 
system returns to its original pre-treatment state. Figure 4.10(b) shows that 
following two perturbations with treatment, the system returns to its original 
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Figure 4.13: Bifurcation diagrams describing how U, I, C and V change as b1 
is varied (r = 0). 
that when b1 = 115.3, the infected cell and virus populations are extinct. The 
exchange of stability occurs where the fixed point at V = 0 becomes stable 
where V coordinate of the original fixed point solution becomes unstable and 
negative. When b1 > 115.3, the fixed points that have positive values are 
unstable. Thus, the model predicts a virus-free equilibrium state when b1 is 
very high. It is unlikely based on parameter estimates from the literature that 
the removal rate parameter would ever have a value this high. Nonetheless, 
the model predicts that increasing efficacy of removal of infected cells from the 
system by the HIV-specific CD8+ T cells is associated with equilibrium states 
whereby the values of I, C and V become successively lower and the value of 
U becomes successively higher. This result is in accordance with the known 
effects of these cells and also the impact of the virus on these cells throughout 
immunopathogenesis. 
Every value of b1 in the range 0 < b1 < 115.3 elicits stability in the system 
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whereby the stable fixed points have positive-valued coordinates. Thus, for 
successively higher values of b1, the host is living with the virus and controlling 
the virus with increasing efficiency. For example, an individual with a removal 
rate of b1 = 0.05 yields a viral setpoint of 4.2, whereby an individual with a 
removal rate of b1 = 0.0005 yields a viral setpoint value of 4.66. 
We must also examine how the system changes as b1 is varied on-treatment. 
Since treatment lowers V substantially, it is likely that the system will be more 
sensitive to small changes in b1 on-treatment. Figure 4.14 shows the how the 
system changes when b1 is varied on-treatment (r = 100) and demonstrates 
an amplified response from the system to changes in b1 . 
0 
G Ol 1 ~: l ll l 
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respect to I 
~ Ol I I! l ll I 
" 
(c) b1 varied with 
respect to C 
(d) b1 varied with 
respect to V 
Figure 4.14: Bifurcation diagrams describing how U, I, C and V change as b1 
is varied (r = 100) 
As anticipated, a bifurcation occurs at a much smaller value of b1 on-
treatment. When b1 = 1.092, a transcritical bifurcation occurs whereby the 
infected cell and virus populations are extinct. This value is much closer to 
the given value for b1 in Table 3.3 and confirms that the fixed points are more 
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sensitive to small changes in b1 on-treatment. Clinically, this would imply that 
differences in removal rates will be more important when the individual is on 
treatment (functional deficiencies imply lower b1 values). Figure 4.15 shows 
the comparison between the bifurcation diagrams when b1 is varied, on and 
off-treatment. For both on and off-treatment scenarios, lower b1 values yield 
lower U values and higher I, C and V values. 
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Figure 4.15: Bifurcation diagrams describing how V changes as b1 is varied on 
and off-treatment. 
Thus, bifurcation diagrams show us that fixed points are stable for a wide 
range of b1 values (0 < b1 < 115.3) off-treatment. However, on-treatment the 
fixed points are much more sensitive to small changes in b1 whereby the fixed 
points are stable for a small range of b1 values (0 < b1 < 1.092). At this 
point, it would be interesting to find out how the system variables respond 
immediately following a treatment interruption for different values of b1. We 
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when b1 = 0.0005 treatment and treatment interruption affect the system in 
the much the same way. That is, treatment causes the infected cell, HIV-
specific CDS+ T cell and virus populations to decay and the uninfected cell 
population to grow. A major difference, as was previously established, is that 
the fixed point solutions are different. That is, b1 = 0.05 yields the stable fixed 
(U, 1, C, V) = (0.63, 6.93, 18.89, 16003.28), 
and b1 = 0.0005 yields the stable fixed point 
(U, I, C, V) = (0.22, 19.63, 19.58, 45296.56). 
When b1 < 0.05, the fixed point values U and C decrease and 1 and V increase. 
Interestingly, the rates at which the variable populations change are also 
different as depicted by the slopes of the variable trajectories. In particu-
lar, when treatment is interrupted at day 200, the rate of change of V when 
b1 = 0.0005 is slightly faster than the rate of change of V when b1 = 0.05 as 
seen in Figure 4.17( a) and (b). The differences in the ways that the variable 
trajectories behave is partly due to the differences between their on-treatment 
numbers. The higher b1 value yields higher values for U and lower values for V 
at the moment when treatment is withdrawn, so this changes the way in which 
they approach equilibrium. Ultimately, immediately following a treatment in-
terruption, the V population grows at a faster rate because the removal rate 
parameter b1 has a lower value. In addition, the U population decays earlier 
(and its slope is steeper) because b1 has a lower value. 
Thus, even though there are no qualitative differences in the system when 
b1 = 0.05 and b1 = 0.0005, quantitatively there are notable differences. These 
results confirm that the removal rate b1 is indirectly related to V. The model 
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This leads to a very important part of this thesis: the clinical and experi-
mental data. In this part of the study, I assess the role of HIV -specific CDS+ T 
cells in controlling the virus load and maintaining stable CD4+ T cell counts. 
In the following Chapter, I outline the experimental assay methodologies used 
in this study. 
Chapter 5 
Immunological Assays -
Methodologies 
5.1 Subjects 
HIV-1-infected individuals were recruited through the Infectious Disease Clinic 
of the St. John's General Hospital, St. John's, Canada. Clinic visits were 
scheduled at approximately 3-month intervals or as necessary for appropri-
ate clinical care. In conjunction with each visit, clinical evaluation was per-
formed, plasma HIV RNA was measured using Amplicor HIV-1 Monitor kits 
(Roche Diagnostic Systems, Mississauga, Ontario, Canada) and peripheral 
blood lymphocyte subsets were assessed by flow cytometry. Ethical approval 
was obtained from the Memorial University Faculty of Medicine Human Inves-
tigation Committee and all participants provided informed consent for blood 
collection and access to clinical and laboratory records. 
88 
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5.2 Lymphocyte Isolation 
Human peripheral blood mononuclear cells (PBMC) were utilized for all tests, 
and all work with HIV-infected blood products was performed in a Level-3 
Biohazard Facility. Blood was collected by venipuncture in vacutainers con-
taining acid-citrate dextrose (ACD) and centrifuged for 10 minutes at 400 g 
(1300 rpm in Beckman T-J6 centrifuge). Plasma was removed and replaced 
by an equal amount of phosphate-buffered solution (PBS - PH 7.2). The 
PBS/cell mixture was transferred to a sterile 50 ml tube, layered over 15 ml 
of Ficoll-paque gradient separation medium (Pharmacia Chemicals, Dorval, 
Quebec, Canada) and centrifuged at 400 g for 30 minutes. Interface cells were 
collected, washed in 30 ml PBS, and centrifuged for 5 minutes. The cells were 
washed again in PBS + 1% fetal calf serum (FCS), centrifuged for 5 minutes 
at 300 g and resuspended in lymphocyte medium (RPMI 1640 with 10% FCS, 
10 mM Hepes, 2 mM 1-glutamine, 1% penicillin/streptomycin, and 2 X w-5 
M 2-mercaptoethanol (Gibco, Invitrogen Corporation, Carlsbad, California)). 
Cells were counted and cryopreserved in approximately 1 ml of sterile freezing 
medium and stored in sterile cryovials at -70°C for one week before transfer 
to liquid nitrogen for longer term storage. 
5.3 Cell counting 
Fifty ul of cell suspension was pipetted into a single well of a 96-well microtiter 
plate (Flow Laboratories, Virginia, USA) in conjunction with 50 ul of Trypan 
Blue (Sigma Chemical Co., St. Louis, Mo.). Trypan blue is an exclusion 
dye that stains dead cellular matter. Cells were counted using a cytometer 
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to obtain a viable cell count. Cell count was represented by total number of 
viable cells per ml of medium. 
5.4 Reanimation of Frozen PBMC 
Lymphocyte medium (10 ml) was pipetted into a sterile 15 ml tube. Cry-
opreserved cells were obtained from liquid nitrogen storage, immediately im-
mersed into a 37°C waterbath and gently agitated until contents were almost 
completely thawed. Cells were then immediately transferred to the 15 ml tube 
containing 10 mllymphocyte medium and centrifuged for 5 minutes at 300 g. 
The cells were then resuspended in 10 ml of fresh medium, counted and cul-
tured at approximately 1 x 106 /ml in a sterile 10 ml tube overnight for direct 
use in experimental assays the following day. 
5.5 Infection of PBMC 
PBMC to be infected were counted and centrifuged at 300 g for 5 minutes. 
Pelleted cells were resuspended at 1.0 x 106 /ml and dispensed into 1 ml aliquots 
into labelled sterile 15 ml tubes. Again PBMC were pelleted by centrifugation 
at 300 g for 5 minutes. The supernatant was discarded and cell pellets were 
directly infected with recombinant Vaccinia Viruses (rVVs) at a 2:1 multiplic-
ity of infection (MOl) (2.0 x 106 plaque-forming units (PFU) per 1.0 x 106 
cells) and incubated at 37°C, 5% C02 for 1 hour. Cells were resuspended at 
2.0 x 106 PBMC per ml for direct use in ELispot assay as described in section 
5.6. 
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5.5.1 Recombinant Vaccinia Viruses 
PBMC were infected with the following recombinant vaccinia viruses: vVK1 
(gag/pol), vCF21 (pol), vPE16 (gp160), vNef (nef), and vSC8 (Escherichia 
coli-galactosidase, control) all from the NIH AIDS Research and Reference 
Reagent Program, Rockville, Maryland, USA. 
5.6 ELISpot assay 
Microtiter assay plates (Multiscreen; Millipore Corporation, Billerica, MA) 
were coated with 100 ul of 7.5 ug per ml anti-IFN-')' mAb 1-D1K (Mabtech, 
Stockholm, Sweden) overnight at 4°C. The plates were then washed six times 
with PBS, and 100 ul of recombinant vaccinia-infected PBMC (0.2 x 106 ) were 
added in duplicate and incubated at 37°C, 5% C02 for 16 hours. Negative 
control wells contained unstimulated PBMC and PBMC infected with vsc8 
- a vaccinia virus vector expressing ,8-galactosidase. Positive control wells 
contained 4 ug per ml of phytohemagglutinin (PHA). Following incubation, 
the cells were removed and the wells were washed as described above followed 
by the addition of 100 ul of 1 ug per ml biotinylated anti-IFN-')' mAb 7-B6-1 
(Mabtech) to each well. The plate was incubated for 2 additional hours at room 
temperature followed by washing six times, after which 100 ul of streptavidin 
alkaline phosphatase conjugate (Mabtech) diluted 1/1000 was added to each 
well. The plate was incubated for 1 hour at room temperature, followed by 
another six washes. 100 ul of chromogenic alkaline phosphatase substrate 
(Bio-Rad, Hercules, CA) diluted 1/10 in This buffer was then added to each 
well. After 30-45 minutes, plates were washed with tap water to stop color 
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reactions and then air-dried. Spots corresponding to the footprints of the 
IFN-1-secreting cells were counted with an automated Elispot counter (Zellnet 
Consulting, New Jersey). Responses were considered positive if the number 
of spots was more than twice the negative control and greater than 50 per 
million PBMC. Results are expressed as spot forming cells per million PBMC 
(SFC per 106 PBMC) following subtraction of negative controls whereby a 
spot-forming cell is an IFN-1-producing cell. 
Chapter 6 
Clinical and experimental 
results 
The study cohort included 22 HIV-1-infected individuals and represents in-
fected individuals with a variety of disease progression patterns in the chronic 
phase of infection. Table 6.1 summarizes the complete set of sample dates for 
each study participant and includes T cell counts, virus loads and treatment 
status at the time that each sample was taken. Sample dates are arranged 
chronologically. These particular samples were used in experimental assays to 
assess HIV -specific CDS+ T cell activity in the contexts of high and low virus 
loads. Virus loads (VL) that are <1.7 or <2.6 (depending on the sensitivity 
of the RNA detection assay used) are considered undetectable. 
93 
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Table 6.1: Summary data for study participants 
subject CD4+ T cells CD8+ T cellsa VLb sample date treatment 
status 
1 280 1360 1 3.75 1 1/12/2004 1 on 
3 51 1122 4.87 9/30/1999 off 
270 954 <1.7 10/9/2003 on 
255 765 <1.7 12/23/2004 on 
17 507 624 1 3.66 1 12/9/2004 1 off 
20 285 1045 <2.6 4/19/1999 on 
374 1342 <1.7 4/17/2000 on 
378 1008 <1.7 8/17/2000 on 
35 621 1173 3.25 8/26/1999 on 
44 630 864 2.35 11/6/2003 on 
51 186 1782 5.17 9/9/1998 on 
104 897 4.44 1/30/2003 on 
403 2201 <1.7 9/25/2003 on 
55 305 1780 1 <1.7 1 1/27/1997 1 on 
60 <1 476 4.93 12/12/2001 on 
<1 318 >5.88 11/6/2003 off 
a - T cell counts are expressed as the number ofT cells/ul of peripheral blood (linear scale) 
b- VL are expressed as the number of HIV RNA copies/ml of plasma 
ND- not done 
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Table 6.1: Summary data for study participants, cont'd 
subject CD4+ T cells CDS+ T cellsa vu sample date treatment 
status 
64 608 688 2.46 8/30/1999 on 
629 799 3.05 3/14/2002 on 
570 1121 <1.7 3/9/2004 on 
71 1624 870 <1.7 12/21/2001 on 
1479 957 <1.7 5/16/2002 on 
1161 1188 3 10/10/2002 off 
1102 1392 3.96 3/1/2004 off 
962 1300 4.37 9/13/2004 off 
76 490 817 4.51 3/6/1997 off 
570 480 <1.7 2/8/2001 on 
507 481 2.13 8/29/2002 on 
83 165 649 5.04 6/26/2003 off 
72 240 3.29 11/27/2003 on 
92 663 731 <1.7 6/3/1999 on 
644 1764 4.8 1/15/2004 off 
CHAPTER 6. CLINICAL AND EXPERIMENTAL RESULTS 96 
Table 6.1: Summary data for study participants, cont'd 
subject CD4+ T cells CDS+ T cellsa VLb sample date treatment 
status 
98 209 385 3.84 11/17/1999 on 
448 798 <2.6 2/14/2002 on 
117 64 1040 3.32 12/16/1999 on 
144 1752 3.54 4/27/2000 on 
136 400 416 4.2 1/24/2000 off 
162 261 3.15 7/5/2001 on 
187 296 4.42 5/27/2002 off 
253 319 4.91 12/15/2003 off 
200 320 4.88 5/27/2004 off 
140 1 540 2772 1 4.31 1 1 ;1oj2oo3 1 off 
157 400 1320 5.12 11/7/2002 off 
ND ND <2.6 8/12/2004 on 
166 1 276 696 1 <1.71 5/13/2004 1 on 
174 513 1782 4.51 11/13/2003 off 
442 1716 3.26 5/3/2004 on 
176 418 1210 1 <1.71 1;s;2oo4 on 
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6.1 Clinical laboratory data 
Each HIV-infected individual in the cohort fits into one of two groups based 
on differences in disease progression patterns (rates) as indicated by clinical 
laboratory data. The groups are fast progressors and slow progressors. HIV-
infected individuals who experienced rapidly falling CD4 counts and rapid 
viral rebound following treatment interruption (off-treatment), as indicated 
by clinical laboratory parameters, were classified as fast progressors. HIV-
infected individuals who maintained stable CD4 counts and virus loads at 
controllable levels following treatment interruption (off-treatment), also indi-
cated by clinical laboratory parameters, were classified as slow progressors. 
A clear distinction between fast and slow progressors can be illustrated with 
this example. Subject 136 had an on-treatment undetectable virus load ( <2.6) 
on 11/20/2001 (not shown in Table 6.1 since this sample was not tested by 
Elispot) which rapidly rebounded to 4.42 by 5/27/2002 when treatment was 
withdrawn and peaked at 4.91 on 12/15/2003. The mean virus load during 
the off-treatment timeframe was 4.53. Concomitantly, CD4 counts rapidly 
fell from 220 on 11/20/2001 to 187 on 5/27/2002 and troughed at 176 on 
05/05/2003. The mean CD4 count during the off-treatment timeframe was 
216. Thus, subject 136 is a fast progressor. Subject 71 had an undetectable 
virus load ( <1.7) on 5/16/2002 that slowly rose to 4.37 by 9/13/2004 when 
treatment was withdrawn and subsequently fell again to 3.98 while treatment 
remained off (not shown in Table 6.1). The mean virus load during the off-
treatment timeframe was 3.61. CD4 counts remained high, troughing at 720 
in the off-treatment timeframe. The mean CD4 count during the off-treatment 
timeframe was 937. Thus, subject 71 is a slow progressor. 
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The mean off-treatment trough CD4 counts (nadir) and peak virus loads 
for each of the 22 study subjects were used as indicators of disease progression 
rates and grouped according to a cluster analysis: a multivariate technique 
designed to create groups within multivariate data. 
Table 6.2: Summary off-treatment data for fast progressors 
I subject I peak VL I trough CD4 count I 
1 5.49 200 
3 4.87 28 
20 5.5 76 
35 4.77 245 
51 5.01 117 
55 5.54 311 
60 >5.88 0 
76 4.83 409 
83 >5.88 40 
92 4.93 340 
98 5.73 69 
117 5.84 27 
136 4.91 176 
157 5.81 40 
166 >5.88 221 
174 5.16 380 
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Table 6.3: Summary off-treatment data for slow progressors 
I subject I peak VL I trough CD4 count I 
17 4.32 296 
44 4.37 480 
64 3.72 594 
71 3.76 925 
140 4.32 462 
176 1.7 245 
99 
The cluster analysis revealed two distinct groups (p<0.05) that adhered 
to the above principles, yielding 16 fast progressors and 6 slow progressors 
summarized in Tables 6.2 and 6.3. See Appendix for statistical reference. 
The fast and slow progressor grouping reveals notable differences in trough 
CD4 counts and peak virus loads between the two groups. In the fast pro-
gressor group, virus loads are greater than 4.7 HIV RNA copies/ml blood and 
trough CD4 counts range from 0 to 409. In the slow progressor group, virus 
loads are less than 4.4 and CD4 counts range from 245 to 925. As discussed 
in the introduction, a controlled virus load is considered to be below 4.5 and 
an uncontrolled virus load is considered to be above 4.5 HIV RNA copies/ml 
blood. Thus, the fast progressors do not appear capable of inherently suppress-
ing the virus load to controllable levels during the chronic phase of infection, 
but the slow progressors do. 
For further comparison of the groups, the means and medians of the trough 
CD4 counts and peak virus loads were calculated and are shown in Table 6.4. 
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Table 6.4: Comparison of off-treatment trough CD4 counts and peak virus 
loads for fast and slow progressors 
I fast progressor I slow progressor I 
mean VL 5.38 ± 0.44 3.7 ± 1.02 
CD4 167 ± 138 500 ± 244 
I median I ;~4 ~ 5.5 4.04 147 471 
Fast and slow progressor groups differ significantly in mean off-treatment 
trough CD4 counts and peak virus loads (Kruskal-Wallis rank-sum test; p<0.05) 
revealing striking differences between the groups. The mean trough CD4 count 
in the fast progressor group is 3-fold lower than in the slow progressor group 
and the peak virus load is 1.5-fold higher. Subject 176 had an undetectable 
off-treatment virus load which skews the slow progressor virus load data re-
sulting in a high standard deviation. This most likely arises due to residual 
drugs in the host system. This individual resumed treatment following a brief 
(one month) treatment holiday and subsequent measures of virus load remain 
undetectable ( < 1. 7). 
Thus statistical analysis of clinical lab data shows that among the 22-
member cohort, 16 are fast progressors and 6 are slow progressors as deter-
mined by a cluster analysis of nadir and peak virus load data and the principles 
outlined at the beginning of this section. Having classified each member of the 
cohort as a fast or slow progressor, the role of HIV -specific CDS+ T cells in 
contouring these classifications can be assessed. 
CHAPTER 6. CLINICAL AND EXPERIMENTAL RESULTS 101 
6.2 Experimental observations 
If your experiment needs statistics, you ought to have done a better 
experiment. - Ernest Rutherford (1S71-1937) 
6.2.1 Quantity of responses 
To assess the role of HIV-specific ens+ T cells in contouring the fast and 
slow progressor groups, measurements of IFN-1 production from HIV-specific 
ens+ T cells were taken for each of the 22 members of the cohort. The number 
of measurements taken for each individual was based on sample availability 
and ranged from 1 to 5. (See Table 6.1.) When possible, measurements were 
taken in pairs when virus loads were either low or high to enable a comparison 
between the HIV-specific ens+ T cell activities in both contexts. One HIV-
specific ens+ T cell is represented by a spot on an Elispot plate. A minimum 
of 50 spot-forming cells (SFe) (background number) per million PBMe was 
considered a positive response. 
The goal of these experiments was to assess each subject's ability to mount 
HIV-specific memory T cell responses against stimulating agents (HIV /vaccinia 
constructs) in the contexts of high and low virus loads and to evaluate the 
importance of both the quantity and quality of these cells in maintaining a 
controllable virus load. We hypothesized that the magnitudes of all positive 
responses, as defined above, would correlate with virus load. We also hypoth-
esized that the magnitudes of responses in the fast progressor group would 
be lower than in the slow progressor group in the contexts of low and high 
virus loads, since the mean virus load of a fast progressor is higher than the 
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mean virus load of a slow progressor. The Elispot results for fast and slow 
progressors are shown in Tables 6.5 and 6.6. 
Table 6.5: Compiled Elispot results - fast progressors 
3 9/30/1999 60 448 388 896 508 4.02 off 
10/9/2003 78 258 465 801 336 <1.7 on 
12/23/2004 25 83 45 153 108 <1.7 on 
20 4/19/1999 470 413 ND 883 883 <2.6 on 
4/17/2000 405 383 ND 788 788 <1.7 on 
8/17/2000 403 388 208 999 791 <1.7 on 
35 I 8/26/1999 I 245 11835 I ND I 2080 2080 I 3.25 I on 
51 9/9/1998 3 68 38 109 71 5.17 on 
1/30/2003 70 528 68 666 598 4.44 on 
9/25/2003 33 235 78 346 268 <1.7 on 
55 I 1/20/1997 I 0 I 148 I ND I 148 148 I 4.66 I on 
60 12/12/2001 0 3 5 8 3 4.93 on 
11/6/2003 0 25 28 53 25 >5.88 off 
76 3/6/1997 50 460 ND 510 510 4.51 off 
3/6/1997 80 425 33 538 505 4.51 off 
2/8/2001 35 83 ND 118 118 <1.7 on 
8/29/2002 285 465 ND 750 750 2.31 on 
83 6/26/2003 1258 1538 ND 2796 2796 5.04 off 
11/27/2003 268 673 ND 941 941 >5.88 on 
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Table 6.5: Compiled Elispot results- fast progressors, cont'd 
subject sample date vnef vvk1 vpe16 combined vnef+vvk1 VL on/off 
92 6/3/1999 530 755 288 1573 1285 <1.7 on 
1/15/2004 4208 3230 843 8281 7438 4.8 off 
98 11/17/1999 95 90 8 193 185 3.84 on 
2/14/2002 160 203 48 411 363 <2.6 on 
117 12/16/1999 198 118 133 449 316 5.15 on 
4/27/2000 225 175 228 628 400 3.54 on 
136 1/24/2000 1070 1550 ND 2620 2620 4.2 off 
7/5/2001 80 145 100 325 225 3.15 on 
5/27/2002 405 510 573 1488 915 4.42 off 
12/15/2003 1240 408 533 2181 1648 4.91 off 
5/27/2004 120 83 40 243 203 4.88 off 
157 11/7/2002 80 543 128 751 623 5.12 off 
8/12/2004 23 55 20 98 78 <2.6 on 
166 1 5/13/2004 1 33 l1s23 1 350 1 1906 1556 I <1.7 I on 
174 11/13/2003 1120 1778 780 3678 2898 4.51 off 
5/3/2004 733 775 433 1941 1508 3.26 on 
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Table 6.6: Compiled Elispot results- slow progressors 
sample date 
17 12/9/2004 338 295 4023 3728 3.66 off 
44 11/6/2003 5 468 773 305 2.35 on 
64 8/30/1999 30 3600 823 4453 3630 2.46 on 
3/14/2002 88 2278 2113 4479 2366 3.05 on 
3/9/2004 40 1310 1025 2375 1350 <1.7 on 
71 12/21/2001 1280 1240 293 2813 2520 <1.7 on 
5/16/2002 855 863 218 1936 1718 <1.7 on 
10/10/2002 260 990 350 1600 1250 3 off 
3/1/2004 1003 635 215 1853 1638 3.96 off 
9/13/2004 700 395 228 1323 1095 4.37 off 
140 7/10/2003 1 1668 1 1555 1 1458 4681 3223 1 4.31 1 off 
176 1/8/2004 1 43 1 620 1 45 708 663 I <1.7 I on 
vnef - vaccinia virus vector expressing HIV nef 
vvk1 - vaccinia virus vector expressing HIV gag/pol 
vpe16- vaccinia virus vector expressing HIV env 
ND- not done 
Tables 6.5 and 6.6 show a broad range of combined responses both in on 
and off-treatment contexts, as seen in bold text. The number of SFC produced 
by the 16 fast progressors varies from 8 SFC (subject 60) to 8281 SFC (subject 
136) per million PBMC, whereas the number of SFC produced by the 6 slow 
progressors varies from 708 SFC (subject 176) to 4681 SFC (subject 140) 
per million PBMC. The range in the number of SFC is broader in the fast 
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progressor group indicating more variability in the numbers of SFC in this 
group. There are statistical outliers in the fast progressor data set, but the 
variability does not simply arise due to the presence of these statistical outliers. 
When the statistical outliers in the fast progressor group (53 SFC- subject 60; 
8281 SFC- subject 92) are omitted, the range in the number of SFC produced 
by the fast progressors changes to 98 SFC (subject 157) to 3800 (subject 1), 
which, in spite of its similarity to the range of responses produced by the 
slow progressor group, is still more variable. This becomes apparent when the 
means and standard deviations are compared in Table 6. 7. The on-treatment 
number of SFC on the sample date 12/12/2001 for subject 60 is not positive 
(<50 SFC/106 PBMC) thus are considered to be zero. 
The data in the fast progressor group is not normally distributed (p<0.05) 
as confirmed by a continuous fitting distribution Shapiro-Wilk test statistic 
for normalcy, whereas the data in the slow progressor group is normally dis-
tributed (p>0.05). The non-normal distribution of the fast progressor data 
lends to the variability of the data as it produces a higher standard deviation. 
Some samples in the fast progressor group were not tested for responses 
against vpe16 indicated by the ND (not done) label. For statistical purposes, 
the column showing responses against vpe16 is omitted in order to suitably 
compare the fast and slow progressor groups. We chose not to simply omit the 
individual sample dates (rows) that included vpe16 as a test antigen in order to 
maximize the number of fast progressor samples. The range of responses in the 
fast progressor group becomes 71 SFC (subject 51) to 7438 SFC (subject 92) 
and the range of responses in the slow progressor group becomes 305 SFC to 
3728 SFC when the vpel6 column is omitted. As was the case in the combined 
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data set, the fast progressor vnef+vvk1 data set is not normally distributed 
(p<0.05) whereas the slow progressor data set is (p>0.05). In addition, the 
higher variability within the fast progressor data set remains. The numbers of 
SFC on sample dates 12/12/2001 and 11/6/2003 for subject 60 (highlighted) 
are not positive (<50 SFC/106 PBMC) thus are considered to be zero. 
To further assess any quantitative differences in the numbers of SFC be-
tween the fast and slow progressor groups, the means and medians were cal-
culated for on and off-treatment data, shown in Table 6. 7. 
Table 6.7: Comparison of mean and median HIV-specific CD8+ T cell re-
sponses to vnef + vvk1 in fast and slow progressors for different VL 
on off 
mean fp VL 3.04 ± 1.33 4.63 ± 0.35 
SFC 747 ± 795 1879 ± 2106 
sp VL 2.09 ± 0.54 3.86 ± 0.56 
SFC 1793 ± 1149 2187 ± 1206 
median fp VL 2.6 4.51 
SFC 400 915 
<1.7 3.96 
1718 1638 
On-treatment mean numbers of SFC in the slow progressor group are sig-
nificantly higher than in the fast progressor group (p<0.05). This suggests 
that fast and slow progressors make different amounts of SFC on-treatment 
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when the virus load is reduced. Conversely, there is no significant difference 
between off-treatment numbers of SFC (p>0.05) between the two groups sug-
gesting that both groups have similarly high numbers of off-treatment SFC. 
There is a significant difference between the on and off-treatment numbers 
of SFC (p<0.05) in the fast progressor group, but not in the slow progressor 
group (p>0.05). In fact, in the slow progressor group the number of SFC does 
not change considerably despite an approximate 2-log change in virus load. 
Thus, refering to the hypothesis in subsection 6.2.1, the magnitude of positive 
SFC responses in the fast progressor group are indeed lower than in the slow 
progressor group. In addition, in the fast progressor group, the magnitude of 
positive SFC responses positively correlates with the virus load: higher mean 
virus loads are associated with higher numbers of SFC. However, in the slow 
progressor group, the magnitude of positive SFC responses negatively corre-
lates, if anything, with the virus load: higher mean numbers are associated 
with lower virus loads. Thus, the data show that there are significant quanti-
tative differences in the numbers of SFC between the fast and slow progressor 
groups in the contexts of high and low virus loads. 
Notably, off-treatment, the virus load was maintained at controllable levels 
(3.S6) in the slow progressor group in the presence of high frequencies of SFC 
(21S7) which implies that these cells are able to control the virus to suppress 
the virus load. In the fast progressor group, this is not the case. Although the 
mean off-treatment numbers of SFC (1S79) are high, the mean off-treatment 
virus load is also high ( 4.63). Therefore, even in the presence of high quantities 
of HIV -specific ens+ T cells, viral control is not achieved in the fast progressor 
group. This implies that the quantity of HIV-specific ens+ T cells, although 
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important in controlling the virus, is not the only factor. This, in turn, implies 
that the HIV-specific ens+ T cells in the two groups are qualitatively different. 
Subject 92 is a good example of this observation. Even though the magnitude 
of SFe is extremely high off-treatment (743S), the virus is not under control, 
as indicated by the high off-treatment virus load (4.S). 
6.2.2 Quality of HIV-specific CDS+ T cells 
The data imply that the HIV -specific ens+ T cells in the fast and slow pro-
gressor groups differ qualitatively. The fact that the range of SFe responses in 
the fast progressor group (7S-7 43S) is broader than the slow progressor group 
(305-372S) is one point that implies qualitative differences. That is, the level 
of positive responses fluctuates more in the fast progressor group implying 
lack of stability in these responses. In addition, the small change in the mean 
numbers of on and off-treatment SFe in the slow progressor group indicates 
that the responses are more stable than the responses in the fast progressor 
group. 
Fast progressors may have impaired HIV-specific ens+ T cell responses in 
terms of proliferative ability and in general, maturation. If the HIV-specific 
ens+ T cell responses were functionally impaired, virus loads would poten-
tially be consistently high due to a lack of control of viral replication by these 
cells [Appay et al., 2000; Hess et al., 2004; Shankar et al., 2000]. Simply put, 
these cells may not be able to do what they are meant to do. In short, higher 
virus loads are associated with functionally impaired cells and lower virus loads 
are associated with functionally intact cells that impose "negative pressure" 
on the virus [Betts et al., 2005]. 
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To illustrate the potential impact of qualitative differences of the HIV-
specific CD8+ T cells in the fast and slow progressor groups and to assess the 
stabilities of these responses, subjects 136 and 71 were selected from the fast 
and slow progressor groups as representatives of each group. These subjects 
were selected based on the relatively high number of samples (5) available for 
each. The high number of samples taken over a period of approximately 3 
years allows us to clearly represent how the SFC and virus loads change with 
respect to time over an extended period of time and to examine the stability 
of these responses in different treatment contexts. 
To illustrate potential differences in qualities of responses, the number 
of SFC per million PBMC and the virus loads for these subjects (y-axis on 
linear and log10 scales, respectively) were graphed against sample dates (x-
axis) as seen in Figure 6.1. The number of SFC are represented by bars 
(off-treatment samples are black; on-treatment samples are grey) and virus 
loads are represented by lines. Undetectable virus loads ( < 1. 7) were assumed 
to be the minimum cut-off value for the virus load and are therefore portrayed 
as "zero" values on the graphs as seen on the secondary y-axis on the right. 
All SFC responses are positive (> 50 SFC above background). 
Subject 136 is initially off treatment. The virus load is detectable ( 4.2) on 
this sample date (1/24/2000). The number of SFC is highest (2620) on this 
date. The virus load subsequently falls (3.15) upon initiation of treatment by 
7/5/2001. This is associated with an 11-fold reduction in the number of SFC 
(225). Subsequent to treatment withdrawal, over the following three years, the 
virus load steadily climbs (4.42), peaks (4.91) until it reaches a setpoint level 
( 4.88). Concomitantly, the number of SFC also steadily climbs (915), peaks 
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(a) Representative fast progressor, 136 (b) Representative slow progressor, 71 
Figure 6.1: Comparison of SFC/106 PBMC and virus loads for the fast and 
slow progressor representatives 
(164S), but then drops S-fold (203) by 5/27/2004. The number of SFC drops 
while the virus load remains high and therefore these responses are unstable. 
The fact that the virus load remains high despite potent anti-HIV responses 
(high numbers of SFC) implies that these cells may be ineffective and the 
responses unstable. If these cells were functioning normally and efficiently to 
remove infected cells and to impose anti-viral pressure on the virus, the viral 
loads would most likely be reduced and perhaps the responses would be more 
stable. When the virus load rebounds following treatment interruption, the 
HIV-specific ens+ T cells respond rapidly by proliferating due to increased 
antigen load, but do not maintain these proliferative responses over time, as 
indicated by the drop in number of SFC. Concomitantly, they do not clear 
the virus effectively to reduce the virus load or maintain it at controllable 
levels. The inability of the HIV-specific ens+ T cells in the fast progressor 
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representative to control the virus off-treatment demonstrates that these cells 
are ineffective in vivo. This ineffectiveness may be due to stunted maturation. 
If these cells were preterminally differentiated, they would not serve their roles 
as fully-functional effector cells. This may manifest in the reduced ability to 
clear infected cells from the system. This supports the theory that the HIV-
specific ens+ T cell responses are functionally impaired in all fast progressors. 
Subject 71 is initially on treatment. The virus load is undetectable ( <1. 7) 
on the first two sample dates. The numbers of SFC are highest (2520 and 171S) 
on these dates. When treatment is withdrawn, the virus load subsequently in-
creases (3.0) by 10/10/2002 and steadily climbs (3.96) over the following two 
years to a setpoint level (4.37) by 9/13/2004. Concomitantly, the number of 
SFC decreases (1250), rises slightly (163S) and then decreases again (1095) 
by the fifth sample date 9/13/2004. The virus load continues to drop (3.9S) 
to lower levels by 3/10/2005 (not shown). The fact that the virus load is 
maintained at controllable levels in the presence of lower stable frequencies 
of HIV-specific cns+T cells implies that these cells are functionally intact; 
or at least more effective than those of the fast progressor representative. 
Prior to treatment interruption, the HIV-specific ens+ T cells demonstrate 
unimpaired proliferative abilities as indicated by high numbers of on-treatment 
SFC. When the virus load rebounds following treatment interruption, the HIV-
specific CDS+ T cells maintain these good proliferative responses over time, as 
indicated by the relatively constant number of SFC. Concomitantly, they clear 
the virus effectively to keep the virus load down and to maintain it at control-
lable levels. The fact that the slow progressor representative demonstrates the 
ability to control the virus via HIV-specific ens+ T cell responses supports 
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the theory that the HIV-specific ens+ T cell responses are more functionally 
intact in slow progressors than they are in fast progressors. 
Therefore, these data indicate that there are qualitative differences between 
the HIV-specific ens+ T cells in the fast and slow progressor groups. 
6.2.3 Comparison of theoretical and experimental data 
When comparing quantitative results obtained mathematically and experimen-
tally, we see that the model accurately predicts on and off-treatment disease 
equilibrium states with respect to HIV-specific ens+ T cell frequencies and 
virus loads. 
Table 6.S: Comparison of theoretical and experimental ens+ T cell responses 
and virus loads 
on off I ratio I 
exp fp VL 3.04 4.63 1.52 
SFC 747 1879 2.52 
math fp v 2.65 4.66 1.76 
c* 1183 1958 1.66 
exp sp VL 2.09 3.86 1.85 
SFC 1793 2187 1.22 
math sp v 2.32 4.20 1.81 
c* 1094 1889 1.73 
* - SFC ~ SFC/106 PBMC; C ~ cells/100ul 
Table 6.S shows that the experimental and theoretical trends are the same 
with respect to HIV -specific ens+ T cell responses and virus loads on and 
CHAPTER 6. CLINICAL AND EXPERIMENTAL RESULTS 113 
off treatment. Since we assume that the fast progressors have impaired HIV-
specific CD8+ T cell responses, we assign a lower value to b1 (infected cell 
removal rate) for the fast progressors. This qualitative difference, represented 
by differences in this parameter between the two groups, yields different equi-
librium values as seen in Table 6.8. In the fast progressor group, the virus 
load is 1.52 times higher off-treatment (than on-treatment) according to ex-
perimental results and is 1. 76 times higher according to the model (infected cell 
removal rate b1 = 0.0005). There are 2.52 times as many SFC off-treatment 
(than on-treatment) and 1.66 times as many HIV-specific cells according to 
the model. In the slow progressor group, the virus load is 1.85 times higher off-
treatment (than on-treatment) according to experimental results and is 1.81 
times higher according to the model (infected cell removal rate b1 = 0.05). 
There are 1.22 times as many SFC off-treatment and 1. 73 times as many 
HIV -specific CD8+ T cells according to the model. The only considerable dis-
crepancies between experimental results and the model are the on-treatment 
numbers of SFC in the fast and slow progressor groups. The model predicts 
smaller differences in on and off-treatment numbers of SFC in the fast pro-
gressor group and larger differences in on and off-treatment numbers of SFC 
in the slow progressor group. These differences arise from the differences in 
the theoretically-determined C values whereby this value is predicted to be 
higher in the fast progressor group, and lower in the slow progressor group 
on-treatment than the experimentally-obtained values. It is important to bear 
in mind that the valuer= 100 was the "selected" treatment parameter value. 
See Chapter 4. Therefore, in the case of the fast progressors, if treatment is 
more efficacious, that is, if the treatment parameter value was higher, then 
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the theoretically-determined value would be lower. A higher r value would 
also reduce the viral set point to a lower level. However, in the slow progres-
sor group, a lower value for r would need to be selected to allow for a higher 
theoretically-determined value. A lower r value would subsequently result in 
a higher viral setpoint. Thus, we can narrow the gap between the theoretical 
and experimental results by selecting a different value for r. 
What is most important in comparing the theoretical and the experimen-
tal results is the relative proportion of the number of SFC to virus load on 
and off-treatment. For example, despite the difference between the absolute 
numbers of SFC in the theoretical and experimental settings, the number of 
SFC is higher off-treatment in both. Likewise, in the slow progressor group, 
the number of theoretically and experimentally-determined SFC are greater 
off-treatment. The fact that the theoretically-determined numbers of SFC are 
more disparate than the experimentally-determined numbers in the slow pro-
gressor group, and less disparate in the fast progressor group, does not take 
away from the predictive potential of the model due to the fact that we can 
modify the theoretically-determined numbers by simply modifying the treat-
ment parameter value to more appropriately describe the efficacy of treatment. 
In summary, I report quantitative and qualitative differences in the HIV-
specific CDS+ T cell responses between two clinically-determined subgroups 
of HIV-1-infected indidviduals. One group, the fast progressors, showed im-
paired responses which matched consistently high virus loads, as determined by 
high off-treatment peak virus loads and high mean on and off-treatment virus 
loads. Another group, the slow progressors, showed stable effective responses 
which matched virus loads that were at controllable levels as determined by 
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low off-treatment peak virus loads and low mean on and off-treatment virus 
loads. In the following section, we further examine the reasons for these differ-
ences and the impact that qualitative differences in HIV-specific CDS+ T cells 
has on mathematical modeling of HIV-immunopathogenesis and the effects of 
treatment interruption. 
Chapter 7 
Discussion and conclusions 
The novel mathematical model of HIV immunopathogenesis I constructed pre-
dicts the existence of a single stable fixed point. Although global stability of 
the stable fixed point had not been demonstrated, numerical simulations have 
not demonstrated the existence of limit cycles chaos or any other phenomena. 
With a single stable fixed point, the initial conditions do not affect the eventual 
arrival at this single equilibrium point. These initial conditions represent the 
initial numbers of T cells and the virus load. Therefore, the model predicts 
that regardless of the initial number of T cells or the amount of virus that 
enters the system or where/how it enters the system at the point of infection, 
the outcome of infection, as defined by the numbers of T cells at equilibrium 
and the viral setpoint, does not change. This is not to say that all infected 
individuals will have the same setpoint. The setpoint is determined by the 
parameter values used in the model. 
Naturally, as previously predicted, the existence of a single stable fixed 
point means that treatment cannot be used to reset the viral setpoint. When 
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treatment is imposed on the system, the system behaves according to known 
effects of treatment on the HIV-infected immune system. The virus load falls 
and the uninfected CD4+ T cell population rises. Bifurcation analysis con-
firmed an indirect relationship between the treatment parameter r, or the 
efficacy of treatment, and the viral setpoint V and a direct relationship be-
tween r and the number of infected cells at equilibrium, U. Thus, treatment 
functions to transiently lower the viral load but not to permanently reduce it 
to a lower setpoint level. 
Another implication of a single stable fixed point is that death is never 
predicted as a stable state. All biological systems are finite. Thus, future 
work will involve modifying the model to predict at least two stable biologically 
relevant equilibrium states: one to represent the host living with virus and one 
to represent the death of the host. A way to do this may involve including an 
additional term in the model that represents interactions between HIV -specific 
CD4+ T cells and HIV-specific CDS+ T cells. 
The model also predicted a virus-free equilibrium state at very high treat-
ment values. That is, the model is sensitive to small changes in drug efficacies 
that result in very low on-treatment virus loads. This result implies that, ac-
cording to the model, it is theoretically possible to clear the virus from the 
system if treatment is virtually 100% effective and maintained ad infinitum. 
However, treatment is never this effective in reality or maintained ad infinitum. 
This result simply reflects the fact that if treatment reduces the viral produc-
tion rate beyond some threshold, the virus population decays faster than it 
grows. However, even if the virus population does decay, which it does in 
some individuals, this decay is not fast enough for eradication to occur during 
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a normal lifespan. 
It is important to reiterate that the single stable fixed point is the product 
of a particular parameter set. If the parameter set was different, it is possible 
that the model would predict more than a single stable equilibrium point. 
The existence of at least two stable fixed points would allow for alternate 
states of being resulting in more than a single potential outcome in terms 
of equilibrium states. For example, an infected individual may tend to an 
equilibrium state whereby they are controlling the virus reasonably well if their 
CD4 + T cell count is above some threshold. In addition, the model solutions 
for the chosen parameter set approach the single stable fixed point according 
to numerical simulations and bifurcation diagrams. However, it should be 
noted that for a different parameter set, the model may in fact predict the 
existence of more complicated behaviour such as limit cycles. In this thesis, 
more complicated behaviours were not observed: all solutions for the chosen 
parameter set approached the single stable fixed point. 
An analysis of the model without the explicit inclusion of a population 
of cells representative of an HIV -specific CDS+ T cell population showed two 
important things. One, the predicted single stable fixed point value obtained 
from analysis of the three-dimensional system comprised equilibrium values 
representative of an HIV-infected individual not controlling the virus. The 
same parameter set was used in both the three and four-dimensional models. 
Two, the treatment parameter had to be higher to induce analogous effects 
on the three-dimensional system. These observations reflect the important 
role of HIV -specific CDS+ T cells in controlling the virus, at least in the 
theoretical setting, and provide support for the importance of including this 
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variable explicitly in the model. Therefore, the model reflects the dual role of 
HIV-specific CDS+ T cells and antiretroviral treatment to suppress the virus 
load to lower levels. This makes the model strong and reasonable with respect 
to accurately describing immunopathogenesis and the effects of treatment. 
The C equation in the four-dimensional model imposes a term on the in-
fected cell equation that removes infected cells from the system at a particular 
rate. Clinical data showed that the HIV-infected individuals can be catego-
rized as fast or slow progressors. We hypothesized that the rate of removal 
of infected cells partially dictates status as one or the other. That is, fast 
and slow progressors have different removal rate parameter values. Bifurca-
tion diagrams supported this hypothesis. An inverse relationship was observed 
between the removal rate and the infected cell and virus populations at equi-
librium. Lower values of b1 , or the removal rate parameter, were associated 
with higher fixed point values for infected cells 7 and viral loads V, and lower 
fixed point values for uninfected cells U. Higher fixed point values for V and 
lower fixed point values for U are typical of a fast progressor. Disease progres-
sion was defined by both the rate of viral rebound and the loss of HIV -specific 
CD4 + T cells immediately following a treatment interruption and by the val-
ues of the fixed point coordinates U and V in the model. Therefore, an inverse 
relationship was observed between disease progression and the removal rate. 
Disease progression was found to be slower when the removal rate was higher 
and thus fast progressors are assumed to have a lower removal rate parameter 
value than slow progressors. 
The model predicts that differences in removal rates of infected cells (differ-
ences in fast and slow progressors), are more significant when treatment is on. 
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When treatment was off, a bifurcation occured at a considerably higher value 
of b1 than when treatment was on. Knowing this, we investigated whether 
treatment interruptions could be used to boost HIV -specific ens+ T cell ac-
tivity (as determined by the trajectories in the time series plots) during the 
off-treatment phases to lower the viral setpoint, even when the removal rates 
are different. The model predicted that this could not happen, regardless of 
the value of b1, unless the value of the rate actually changed during infection. 
Therefore, since the rates are constant, the model predicts that treatment in-
terruptions can transiently boost HIV-specific ens+ T cell frequencies but 
cannot be used to reset the viral setpoint. It seems as though the removal 
rate should increase with increased HIV -specific ens+ T cell frequency, but 
it does not. This rate remains constant and the changes in the HIV-specific 
ens+ T cell population are the result of the value of the parameter, and not 
by the number of cells at any given point. 
Due to factors such as eTL exhaustion, the removal rate parameter very 
likely becomes smaller as the disease progresses. Theoretically, the removal 
rate parameter could be written as a function of the virus, which inevitably, 
would cause the system to elicit different behaviours. Future work will involve 
replacing one or more constant parameters by functions of either variables or 
time. 
Experimental observations showed distinct differences between the clinically-
determined fast and slow progressor groups. The number of SFe (number of 
HIV-specific cells producing IFN-1) varied quantitatively both within the fast 
and slow progressor groups, and within on and off-treatment settings. Experi-
mental evidence supports the theory that there are also qualitative differences 
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between the SFe in the fast and slow progressor groups. Future work will 
involve determining why this is and incorporating this into the model. 
There are at least several causes for diminished functional ability of HIV-
specific ens+ T cells but all are spurred by the presence of HIV. Whether 
it is a result of the loss of help from HIV-specific en4+ T cells [Lichterfeld 
et al., 2004; Yue et al., 2004], or high turnover of HIV-specific ens+ T cells 
leading to exhaustion, it is evident that disease progression is linked to the 
inability of HIV-specific ens+ T cells to do what they are meant to do. It 
is therefore likely that infected individuals who progress quickly through dis-
ease (fast progressors) have decreased IL-2 production and a larger fraction 
of preterminally differentiated cells resulting in overall loss of control of viral 
replication which translates into low en4 T cell counts and high virus loads. 
On the other hand, infected individuals who do not progress quickly through 
disease (slow progressors) have normal IL-2 production and a larger fraction 
of terminally differentiated cells [Betts et al., 2005]. 
We can further speculate as to how the HIV -specific ens+ T cells exam-
ined in the HIV-1-infected individuals in this study are qualitatively different. 
Functionally intact HIV-specific ens+ T cells produce cytokines such as IFN-
'Y and IL-2 and can differentiate into terminally-differentiated effector eTL 
as part of normal immune responses against the virus. Functionally impaired 
cells are characterized by a loss of ability to produce and respond to these cy-
tokines and to fulfill functional effector eTL duties [Wherry & Ahmed, 2004; 
Kristensen et al., 2002; Appay et al., 2000]. Studies relate progressive HIV 
infection to decreased IL-2 production by HIV-specific T cells [Zimmerli et al., 
2005; Kinter & Fauci, 1996; Ghezzi et al., 1997]. IL-2 is aT cell growth factor 
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and controls the functions ofT cells. HIV-specific CDS+ T cells that become 
activated to impose effector functions require IL-2 to drive clonal expansion 
(proliferation) and different ion into effector and memory T cells. Therefore, 
a lack of sufficient IL-2 to drive clonal expansion of T cells translates into 
progressive infection associated with low CD4+ T cell counts and high virus 
loads. We saw this trend in the fast progressor group. 
Decreased IL-2 production may play a role in improper maturation of HIV-
specific CDS+ T cells into fully functional immune effector cells [Kristensen et 
al., 2002; Wherry & Ahmed, 2004]. Memory differentiation has been linked 
to the appearance of cells with the capacity to produce IL-2 [Kristensen et 
al., 2002; Saparov et al., 1999]. Studies show that progressive HIV disease is 
associated with expansion of HIV-specific CDS+ T cells with a preterminally 
differentiated phenotype [Appay et al., 2000; Champagne et al., 2001; Yue 
et al., 2004]. Preterminal differentiation of HIV-specific ens+ T cells would 
create a pool of cells unable to fulfill effector duties as expected for inapparent 
slow disease progression. 
Studies have also linked progressive HIV infection to loss of functional CTL 
[Chia et al., 1994]. HIV-specific ens+ T cells (CTL) can become function-
ally impaired over time by becoming perforin-deficient [Migueles et al., 2002; 
Appay et al., 2000]. A perforin-deficient HIV-specific CDS+ T cell will have 
diminished capacity to kill virally-infected cells, which would likely translate 
into higher virus loads [S.A. Migueles et al., 2002; Borrow et al., 1994; V. Ap-
pay et al., 2000]. The loss of functional CTL is likely linked to the perpetual 
generation of these cells in response to the presence of the virus. The precursor 
cells for these CTL may also have limited regenerative capacity and eventu-
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ally become deleted or clonally exhausted and disappear completely [Walthers 
et al., 1996; Mackall et al., 1997]. Studies have indeed suggested that HIV-
specific ens+ T cells have a high turnover rate based on progressively reduced 
chromosome telomere length of these cells in HIV-infected individuals and may 
result in the rapid consumption of terminally differentiated HIV-specific ens+ 
T cells. (Each time a cell divides, its telomere length shortens [Allsopp et al., 
1995].) 
Future work may involve assessing the proliferative abilities of HIV-specific 
ens+ T cells by measuring IL-2 responses from clinically-defined fast and 
slow progressors from a larger cohort of infected individuals and thus allow a 
determination of the functional ability of these cells to proliferate in response 
to restimulation. The ratio between the amount of IFN-')' and IL-2 produced 
by the HIV -specific ens+ T cells could be determined for each of the fast and 
slow progressor groups to further define the qualitative differences between 
these cells. 
In addition, assessments of the phenotypic markers for the HIV -specific 
ens+ T cells in the fast and slow progressor groups could be done to deter-
mine potential differences in differentiation stages of the HIV -specific ens+ 
T cells. As previously discussed, progressive disease is associated with skewed 
maturation of memory HIV-specific T cells. Studies designed to delineate the 
phenotypes of the HIV -specific ens+ T cells in fast and slow progressors may 
help to elucidate the reasons why the differentiation pathways are different. 
Maintenance of effective immune responses and stimulation of cellular im-
mune response mechanisms are essential to the health of an HIV-infected in-
dividual. Both mathematical and experimental assessments of the quantita-
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tive and qualitative differences between clinically-defined subgroups of a small 
HIV-infected cohort show that slow progressors have lower off-treatment viral 
set points which are determined by both the quantity of HIV -specific ens+ T 
cells and by their quality. The rate at which these cells remove infected cells 
appears to be linked to the ability of the immune system to suppress the virus 
to controllable levels in the absence of treatment. The HIV-specific ens+ T 
cells are thus more functionally efficient in slow progressors. 
Ultimately, the model indicates that, despite differences in removal rates 
among HIV-infected individuals, treatment interruption can be used to tran-
siently boost HIV-specific ens+ T cell responses but cannot be used to reset 
the viral setpoint. The model predicted that treatment interruption can only 
be used to transiently delay disease progression implying no constructive im-
mune enhancement during the treatment interruption phases. Our results 
thus corroborate that treatment interruption is in fact useful, but limited as a 
means to perturb the system toward a more desirable state. 
The results of this work can be used to promote the potential usefulness 
of interrupting treatment. Ultimately, it is the choice of the individual as 
to whether or not the benefits of interrupting treatment outweigh the risks. 
A month break from the toxic drugs would be a great relief for most and 
if carefully monitored, an individual should, in theory, be able to take these 
breaks. 
Chapter 8 
Appendix 
Cluster 1 of 2 contains 16 cases 
Members Statistics 
Case Distance Variable Min. Mean Max. St.Dev. 
Case 7 0.17 VL 4.77 5.38 5.88 0.44 
Case 8 0.58 CD4 1.43 2.09 2.61 0.42 
Case 9 0.17 
Case 10 0.48 
Case 11 0.26 
Case 12 0.31 
Case 13 0.50 
Case 14 0.53 
Case 15 0.50 
Case 16 0.44 
Case 17 0.31 
Case 18 0.57 
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Case 19 0.35 
Case 20 0.46 
Case 21 0.40 
Case 22 0.38 
Cluster 2 of 2 contains 6 cases 
Members Statistics 
Case Distance Variable Min. Mean Max. St.Dev. 
Case 1 0.46 VL 1. 70 3.70 4.37 1.02 
Case 2 0.48 CD4 2.39 2.66 2.97 0.21 
Case 3 0.08 
Case 4 0.22 
Case 5 0.44 
Case 6 1.43 
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